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Introduction
Zbigniew I. Nowecki, Arkadiusz Jeziorski
During the last few decades there has been a trend 
in breast cancer treatment toward limitation of opera-
tion extensity together with higher individualisation of 
systemic treatment and radiotherapy. Breast cancer 
treatment has evolved into a separate therapeutic area 
requiring specialised knowledge. According to the 
European Society of Mastology (EUSOMA), breast 
cancer patients should have access to multidisciplinary 
care, including: radiologist, oncology surgeon with abil-
ity in breast reconstruction, in close cooperation with 
clinical oncologist, radiotherapist, nuclear medicine 
specialist, specialist in rehabilitation, clinical geneticist, 
psycho-oncologist, psychiatrist, palliative treatment 
specialist, specialised nurse, administrative assistant, 
and social worker. However, the crucial role in diagnosis, 
treatment, follow-up, and outline of treatment strategy 
is played by the oncology surgeon. 
In May 2015 during the 21st Conference of the Polish 
Society of Surgical Oncology, the Section of Breast 
Cancer and Reconstructive Surgery was initiated, estab-
lished by the Polish Society of Surgical Oncology (PSSO) 
(Polskie Towarzystwo Chirurgii Onkologicznej, PTChO) 
Management Board on 3rd October 2014. One of the 
main postulates of the Section members was the devel-
opment of uniform, common recommendations, which 
could guide oncology surgeons treating breast cancer in 
Poland. It was proposed that a discussion platform be 
created, allowing achievement of agreement regarding 
all subjects of interest for surgeons. These actions were 
supported by the PSSO Management Board and the 
National Consultant in surgical oncology.
The consensus should comprise diagnosis, surgery 
treatment, and breast reconstruction. As previously 
mentioned, breast cancer patients should be treated 
with team management; however, the oncology surgeon 
remains a central member of the multi-disciplinary team 
(MDT) qualifying to the treatment and defining the 
type and extension of therapy. According to this, the 
guidelines also included the problems of loco-regional 
conservative treatment and some aspects of systemic 
therapy. Of note, the developed Consensus was not 
aimed at verifying the recommendations in clinical 
oncology, radiotherapy, or other oncological speciali-
ties, but to give substantive suggestions to the oncology 
surgeon regarding which therapeutic option should be 
supported in discussions during MDT meetings. In these 
situations the information was always implemented: 
“MDT decision, suggested standpoint of surgical on-
cologist:…”, which highlights the importance of team 
consensus in each individual therapeutic decision.
The Consensus was prepared based on international 
recommendations, mainly developed by German AGO 
(der Arbeitsgemeinschaft Gynäkologische Onkologie e. 
V. in der Deutschen Gesellschaft für Gynäkologie und 
Geburtshilfe e. V. sowie in der Deutschen Krebsgesells-
chaft e. V.) (http://www.ago-online.de/en/guidelines-mam-
ma/march-2016/) and american NCCN (National Cancer 
Comprehensive Network) (https://www.nccn.org/profes-
sionals/physician_gls/f_guidelines.asp#site).
The Recommendations “Surgical management of 
breast malignancies — Consensus of the Polish Society 
of Surgical Oncology” were developed after the collective 
discussion of nearly 60 members of the Section of Breast 
Cancer and Reconstructive Surgery of the Polish Society 
of Surgical Oncology and many other specialists who 
were giving lectures. The vast majority of the Consensus, 
including basic problems of breast cancer surgery, was 
then publicly discussed and verified upon voting during 
the Section’s meeting on 16th June 2016 in the Maria 
Skłodowska Curie Memorial Cancer Centre and Institute 
of Oncology in Warsaw. The remaining topics were veri-
fied during electronically conducted voting.
During preparation of the Consensus the value of 
each single topic was assessed based on:
 — Oxford Score evidence level (Tab. 1), Oxford Score 
recommendation grade (Tab. 2), AGO recom-
mendation criteria (Tab. 3), and NCCN guidelines 
(recommendations above 2A),
 — Polish Society of Surgical Oncology recommenda-
tion criteria modelled on AGO score and presenting 
the consensus percentage within Consensus Authors 
regarding each discussed issue (Tab. 4).
During discussion of this Consensus all the afore-
mentioned recommendation criteria were available. 
However, for clarity this publication presents only 
PTChO recommendation criteria.
The aim of the presented team publication is the 
outline of substantive frames of our management, as 
well as defining essential conditions for qualification, 
surgical treatment, and perioperative management. We 
would like to have this Consensus as a true “guide” for 
all surgeons treating breast cancer patients. At the same 
time, we highlight that our Consensus is like a “frame”, 
indicating some directions of management. It is worth 
mentioning that sometimes we are forced to treat pa-
tients who need highly individualised treatment, beyond 
this Consensus. In this group of patients, the decisions 
about tailored treatment, giving some benefits, are made 
by a multidisciplinary team.
The development of the guidelines “Consensus of 
the Polish Society of Surgical Oncology under the sub-
stantive auspices of the National Consultant in surgical 
oncology” is an essential strategy of the Polish oncology 
surgeon community because they have achieved, as 
a community, surgical skills and oncological knowledge 
as well as diagnostic-therapeutic possibilities, allowing 
patient treatment in all Polish centres according to the 
most optimal procedures.
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Table 1. Oxford Score of levels of evidence (edited by lek. M. Maczkiewicz)
Level Publication on the topic: therapy/prevention, 
aetiology/harm:
Publication on the topic: prognosis
1a Systematic reviews (with homogeneity) of randomised 
controlled trials
Systematic review (with homogeneity) of inception cohort 
studies; clinical rule validated on a test set
1b Individual randomised controlled trials (with narrow 
confidence interval)
Individual inception cohort study with ≥ 80% follow-up; 
clinical rule not validated on a second set of patients
1c All or none randomised controlled trials All or none case-series
2a Systematic reviews (with homogeneity) of cohort studies Systematic review (with homogeneity) of either 
retrospective cohort studies or untreated control groups in 
randomised controlled trials
2b Individual cohort study (including low quality 
randomised controlled trials e.g. < 80% follow-up)
Retrospective cohort study or follow-up of untreated 
control patients in randomised controlled trials; or clinical 
rule not validated in a test set
2c  “Outcomes Research” or ecological studies “Outcomes research”
3a Systematic review (with homogeneity) of case-control 
studies
—
3b Individual case-control study —
4 Case-series (and poor quality cohort and case-control  
studies)
Case-series (and poor quality prognostic cohort studies)
5 Expert opinion without explicit critical appraisal, or based 
on physiology, bench research or “first principles”
Expert opinion without explicit critical appraisal, or based 
on physiology, bench research or “first principles”
Table 2. Oxford Score of recommendation grade (edited by lek. M. Maczkiewicz)
Grade A Consistent results directly based on Level 1 evidence
Grade B Consistent results directly based on Level 2 or 3 evidence or extrapolated recommendations from Level 1 evidence
Grade C Directly based on Level 3 or 4
Grade D Directly based on Level 5 or problematic/inconsistent/unequivocal Level 2, 3, or 4 evidence
Table 3. AGO recommendation criteria (edited by lek. M. Maczkiewicz)
Recommendation 
level
Recommendation criteria
++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without 
restriction, and should be performed
+ This investigation or therapeutic intervention is of limited benefit for patients and can be performed
+/– This investigation or therapeutic intervention has not shown benefit for patients and may be performed 
only in individual cases. According to current knowledge, a general recommendation cannot be given
– This investigation or therapeutic intervention can be disadvantageous for patients and might not be 
performed
2– This investigation or therapeutic intervention is clearly disadvantageous for patients and should be avoided 
or omitted in any case
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Table 4. Polish Society of Surgical Oncology (PSSO) recommendation criteria, used during assessment of particular 
diagnostic and therapeutic problems in breast cancer patients
Recommendation 
level
Recommendation criteria* Consensus level among 
Consensus authors
2+ This investigation or therapeutic intervention is highly beneficial for 
patients, can be recommended without restriction, and should be 
performed
81–100%
1+ This investigation or therapeutic intervention is of limited benefit for 
patients and is recommended to be performed
61–80%
0 This investigation or therapeutic intervention has not shown benefit for 
patients and may be performed only in individual cases
41–60%
1– This investigation or therapeutic intervention can be disadvantageous for 
patients and is not recommended to be performed
21–40%
2– This investigation or therapeutic intervention is disadvantageous for 
patients and should be avoided
0–20%
*In individual cases, the therapeutic decision is based on criteria of the patient’s clinical state and cancer stage, and is finally developed during an MDT meeting
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A.1. Multidisciplinary treatment  
of breast cancer. Organisational basis 
for a centre of breast cancer diagnosis 
and treatment — Breast Cancer Unit  
in Poland
Arkadiusz Jeziorski, Zbigniew I. Nowecki
Decreasing the extensity of radical operations, 
together with improvement of breast cancer patients 
survival from 45–50% at the end of the nineteenth 
century to 80–90% currently, result from early diag-
nosis, better understanding of tumour biology as well 
as complexity, and multidisciplinary approach to the 
therapy. Currently, breast cancer patients are under 
the supervision of a multidisciplinary team involving: 
surgical oncologist (with competency in breast recon-
struction), radiologist, pathologist, molecular biologist, 
medical oncologist, radiotherapist, specialist in nuclear 
medicine, specialist in rehabilitation, clinical geneticist, 
psycho-oncologist, psychiatrist, specialist in palliative 
care, specialised nurse working in a Breast Cancer Unit 
(BCU), administrative assistant, and social worker. 
A crucial role in this team is still played by a surgical 
oncologist, who coordinates the diagnostic process and 
treatment, and often continues the patient’s follow-up 
for many years.
At the end of the twentieth century, groups of experts 
started make their best efforts to establish BCUs, being 
highly specialised centres, taking complex and modern 
care of breast cancer patients, starting from screening, 
through diagnosis and treatment, to follow-up, together 
with palliative care. EUSOMA (European Society of 
Mastology; 2000, 2013) developed the principles and 
organisational requirements for effective functioning 
of BCUs.
BCU activity includes four stages of intervention:
1.  Diagnosis:
 — confirmation of cancer exclusion,
 — assessment of cancer stage,
 — histological assessment.
2.  Outline of treatment program.
3.  Treatment.
4.  Follow-up after treatment cessation.
In Polish conditions, BCUs should have the privi-
leged to perform without quantitative limits of health 
services; however, their activities should be in line with 
different regulations according to:
 — health services, according to the oncology treat-
ment cart (DiLO cart),
 — reimbursement lists and drug programmes,
 — reports and settlements with the National Health 
Fund (NFZ),
 — waiting lists.
BCUs have the following obligations:
 — authorisation to obtain BCU status (according 
to EUSOMA requirements),
 — adherence to guidelines of management and 
participation in periodic evaluations,
 — maintenance of accurate registration of medical 
documentation to monitor quality,
 — participation in an assessment process regarding 
medial quality and patient satisfaction,
 — performance of periodic audits.
Establishing a BCU in Poland should be conducted 
in three steps:
 — step I — establish pilotage BCU,
 — step II — assess pilot BCU performance,
 — step III — establish full-profile BCU.
During each step, clear criteria of the centre’s ac-
creditation should be adopted (Appendix 1).
The BCU should be accredited by an authority 
(agenda of Ministry of Health) in cooperation with 
scientific societies and national consultants. Because in 
Poland there is no such entire organisation at this time, 
accreditation is possible through EUSOMA and SIS. 
The Polish Society of Surgical Oncology should con-
sider appointing the Committee of Alignment of Breast 
Cancer management with procedures recommended by 
the PSSO (so-called small PSSO accreditation — “Cer-
tificate of Compatibility with PSSO procedures”).
A.2. Detection, and clinical and imaging 
diagnosis of breast cancer
Monika Nagadowska, Ewa Wesołowska
I. Detection
 — Screening based on mammography according to 
American Cancer Society (ACS) guidelines and 
U.S. Preventive Services Task Force (USPFT) 
is recommended in women with no clinical signs 
and symptoms.
 — Contrary to previous guidelines, ACS recommends 
decreasing the age of the screened population 
(after 40 years), and in women ranging between 
40 and 50 years to change the time intervals (every 
12 months).
 — Genetic-based screening is not justified in women at 
overage risk of morbidity, and ACS recommends it 
A. PREOPERATIVE DIAGNOSIS  
AND QUALIFICATION TO SURGICAL OPERATION
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Appendix 1. Proposed criteria of accreditation for Breast Cancer Units (BCUs) in Poland*
Stage I II III
General assumptions
Number of newly diagnosed patients treated in the centre 100 100 150
Main BCU departments: outpatients, diagnostic radiology, pathology in place, surgery, 
chemotherapy, radiotherapy (in place or contracted), data management centre, conference 
room equipped with multimedia (for app. 20 persons)
x x x
Paper or electronic protocols made at each step of diagnosis and treatment 
(medical secretaries)
x x x
Diagnostic radiology
Equipment not older than five years: digital mammography, USG with line 
transducer ≥ 14 MHz, Mammotome biopsy, stereotactic biopsy, MRI with attachment for breast 
(in place or contracted)
x x x
Two radiologists specialised in breast diseases x x x
Each radiologist should assess a minimum of 1000 diagnostic imaging every year x
Descriptions according to the BIRADS system are mandatory x x x
Collaboration with screening centre x x
Training according to EUSOMA criteria x
At least two radiology technicians, performing a minimum of 20 diagnostic images weekly x x
Surgical treatment
At least two specialists in oncology surgery, operating on a minimum of 50 women every year 
(each)
x x x
Ability in breast reconstruction and oncology plastic surgery x x
Bank of prostheses for reconstruction x x
Possibility of SNB in place x x x
Uniform and validated protocols for every procedure x x
Possibility to perform intraoperative mammography and histological examination x x x
Uniform template of referral and signage of preparations x x
Percentage of BCT 25 40 50
Possibility to remove non-palpable lesions x x x
Scientific photography documentation x x x
Separated emplacement to take scientific pictures x x
Pathological diagnosis
Agreed systems for signage of preparations x  x x
Equipment and apparatus not older than 10 years x x x
ER, PR, HER2, and Ki67 assessment x x x
Weekly interdisciplinary team meetings x x x
Analysis of failures  x x
Unified form of test descriptions x x x
Two pathologists assessing yearly at least 50 newly diagnosed cancers x x x
Possibility to store paraffin-embedded blocks for 10 years; collaboration with tissue bank  x x
Molecular assessment; genetics
Possibility to perform assessment of BRCA status (contracted) x x x
Established protocol for definition of positive family history x x
Ensured consultancy of oncology geneticist x x
Chemotherapy
Outpatient chemotherapy (five beds) and stationary chemotherapy (three beds) x x
Equipment not older five years x x x
cont. Æ
89
Surgical management of breast malignancies
in populations at significantly higher risk (e.g. Jewish 
Ashkenazi population).
 — Screening with Magnetic Resonance Imagining (MRI 
of breast) mammography is not justified in women 
at overage risk of morbidity, and is recommended in 
women with confirmed mutation BRCA1/2.
II. Diagnosis
— In preclinical stages, diagnosed during screening 
programmes, further diagnosis is conducted in centres 
prepared for intensified diagnosis and coordinated 
by radiologists.
Stage I II III
Pharmacy preparing cytotoxic drugs in place x x x
Two clinical oncologists x x x
Two oncology nurses administering cytotoxic drugs x x
Radiotherapy
In place or contracted x x x
Own equipment: brachytherapy x x x
Intraoperative radiotherapy x
Irradiation quality control x x
Palliative care
In place or contracted x x
Medical supplies point
Possibility to provide with prostheses, wigs, and other equipment x x
Clinical trials centre
At least 10% of patients enrolled to clinical trials x
Rehabilitation
Developed own program of prophylaxis and treatment of extremity oedema x x  x
Own physiotherapy centre x
Protocols, photography documentation x x x
Registry and epidemiology
Own x x x
Trainings
Organisation once per year of either a regional or national conference x x
Active participation of physicians in two national and two foreign conferences x
Training in Polish or foreign BCU once per year x
Work quality control in BCU
Comprehensive external audit EUSOMA once per year x x
Use of treatment quality measures Minimal Full Full
Minimum weekly interdisciplinary meetings including full team x x
Written treatment plan for each patient x x
More than 90% of patients discussed x x
Verification of treatment plan based on pathological evaluation — including full team x x
Time since diagnosis until treatment commencement (weeks) 5 4 3
During the first visit, it should be possible to perform BAG, BAC, USG, MMR x x x
Information about diagnosis and treatment steps available for the patient either in written or 
electronic form
x x
Patients with advanced cancer should have visits according to different time schemes than for 
the first time (different management and treatment protocols)
x x
An established protocol, available for the patient, regarding the extent and frequency of 
follow-ups after treatment cessation
x x
*The presented organisational principles were based on an unpublished Report of the Committee for BCU, appointed by the Ministry of Health in 2012, of 
which Prof. A. Jeziorski was a member
90
OncOlOgy in clinical practice 2017, Vol. 13, No. 3
 — In preclinical stages, diagnosed outside mammogra-
phy-based screening, further diagnosis is conducted 
in oncological centres.
Presumptive diagnosis
Clinical evaluation includes: medical history, gen-
eral health assessment, menopausal status, and possibly 
biochemistry panel.
Primary tumour assessment includes: physical 
evaluation, mammography (preferably digital) with 
supplemental USG, and breast MRI in special cases.
Detailed diagnosis
After imaging evaluations a decision regarding the 
way and sequence of test verifying imaging lesions in 
breasts is made.
Tissue sample taking (core-needle biopsy and its 
variations) from primary lesion and possible satellite 
lesions/sites is essential during planning of BCT.
Assessment of regional lymph nodes includes: 
physical examination, USG, and possible biopsy (either 
PCI or CB with setting of a marker, when neoadjuvant 
chemotherapy followed by SLNB is planned).
After diagnosis of breast cancer is confirmed, clin-
ical-pathological-mammography correlation is recom-
mended in order to make a decision regarding optimal 
loco-regional treatment.
TNM classification — in every case, a physical exami-
nation and tests are needed during preparation for surgery.
 — In early stages (I–IIA) tests for distant metastases are 
not recommended (so-called “spread tests”), unless 
there are clinical concerns indicating the possibility 
of such lesions.
 — In stage IIB and IIIA “spread tests” should be 
considered, especially when neoadjuvant treatment 
is planned.
 — In stage IIIB “spread tests” are recommended.
After completing the diagnosis process the decision 
should be made in cooperation with the patient about 
psycho-oncology consultancy and consultancy regarding 
fertility prevention.
Also, after completing the diagnosis a decision 
should be made regarding genetic consultancy, depend-
ing on the patient’s age and family history.
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Subject Clinical and imaging 
diagnosis
Analysed problems PSSO recommendation 
Mammography screening according to ACS/USPFT 2015/2016 guidelines (screening since 40 years of 
age, and between 40 and 50 years of age every 12 months)
0
Genetic screening 1–
MRI screening 1–
Medical history, physical examination 2+
Diagnostic mammography with USG of breast and regional lymph nodes 2+
Diagnostic breast MRI 0
Tumour biopsy after imaging completion  2+
Primary lesion biopsy (tissue sample for assessment; full panel of tests: ER/PR, HER2, Ki67) 2+
Fine-needle aspiration of primary lesion in case of suspected cancer 1–
Biopsy of second/next lesion in breast, especially considering BCT 2+
CB biopsy — tissue sample from clinically suspected lymph nodes 0
PCI biopsy — cytological material from clinically suspected lymph nodes 2+
Fine-needle biopsy — only to verify possible metastases 1+
Fine-needle aspiration (FNA) of primary lesions when cancer is suspected 1–
Setting a marker to primary lesion and lymph node 2+
Clinical, imaging, and pathological correlation before making therapeutic decision 2+
Genetic test < 35 years of age and/or familial history 1+
Genetic test > 50 years of age and/or familial history 0
Consultancy of psycho-oncologist 0
cont. Æ
91
Surgical management of breast malignancies
Analysed problems PSSO recommendation 
Consultancy regarding fertility prevention 1+
Screening toward metastases in stage I–II 0
Screening toward metastases in stage III 1+
Test for operation and/or depending of patient’s complaints 2+
Additional tests depending on abnormalities, e.g. AP 1+
Pregnant patients
USG as a preferred test for assessment of breast, abdomen, and pelvis 2+
Chest X-ray and mammography — with use of cover, as safe management 1+
MRI (without gadolinium), if other tests are inconclusive (unequivocal) or there is a suspicion of 
bone or brain metastases
1+
Performing CT, PET, bone scintigraphy — is contraindicated 2+
Assessment of markers: Ca 125, Ca 15-3 is contraindicated 2+
A.3. Pathological diagnosis
Jacek Piechocki, Wojciech P. Olszewski
Appropriate preoperative histological diagnosis, e.g. 
core-needle biopsy of primary lesion in breast and cytol-
ogy of regional lymph nodes, is a basis for therapeutic 
decision-making regarding initiation of the treatment 
of patients with breast cancer. However, appropriate 
postoperative diagnostics allow optimal choice of ad-
juvant treatment.
Diagnostic standards of invasive and pre-invasive 
breast cancer were developed by the Polish Pathology 
Association (Polskie Towarzystwo Patologów, PTP) 
and are available on the PTP website: www.pol-pat.
pl/pl/strony/standardy-129.
Table 1. Basic elements of synoptic histological assessment
Pathology Breast Cancer Report
Infiltrating breast cancer
Patient’s personal data First name, surname; PESEL, etc.
Referring physician’s personal data First name and surname; PWZ (physician’s licence number)
Date of ordering assessment
Date of sending result to the referring physician
1. Operational material type
— Breast gland sample
— Whole breast gland
— Other
2. Surgical procedure
For example, excision with localisation (hook); total mastectomy; others
3. Macroscopic assessment
— Tumour localisation
— Sample size (cm); tumour size (cm)
— Number of primary tumour lesions (concerning invasive cancer)
• single
• multiple number of lesions, size of the greatest lesion
• undefined
— Margins (ink marking and sampling)
• after partial excision: anterior, posterior, superior, inferior, medial, and lateral margin without/with cancer infiltration
• after mastectomy: deep margin on fascia without/with cancer infiltration
— Other organ-specific macroscopic features (conditional assessment):
• for example, skin ulceration, cancer infiltration of pectoral muscle
cont. Æ
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4. Macroscopic assessment features mandatory to assess
—  Histological type of cancer according WHO 
2012 classification:
NST; lobular; others
—  Cancer grade 
• Histological grade (SBR/Nottingham)
G:
—  The largest size of infiltrating component …….. mm
—  DCIS component
—  Surgical margins The most narrow (localisation)  ………….. mm
—  Radicality of excision R0, R1
—  Number of lymph nodes assessed and with metastases Number of sentinel lymph nodes assessed.....................................
Number of all lymph nodes assessed ............................................
Number of lymph nodes with macrometastases............................
Number of lymph nodes with micrometastases.............................
Number of lymph nodes with isolated cancer cells........................
Size of the largest metastatic deposit (if present) .........................
Extra-capsular cancer infiltrations and/or in fat tissue....................
In case of sentinel lymph nodes: 
(sn) — indicates that below six lymph nodes were assessed:
pN0(i-)(sn) with no isolated cancer cells in sentinel lymph nodes
pN0(i+)(sn) isolated cancer cells in sentinel lymph nodes
pN1mi(sn) micrometastases in sentinel lymph nodes
—  Other organ-specific microscopic features 
(conditional assessment)
— Embolus from cancer cells in lymphatic vessels or blood 
vessels
— Invasion of cancer cell surrounding nerves truncus
— Assessment of lesions after preoperative treatment pCR, pPR, 
pNR
—  Clinical stage (S) pTNM stage:
—  Differential diagnosis — minimal immunohistochemistry 
panel
— For diagnosis of myoepithelial cells: CK5/6, CK14, CK17, p63, 
SMMHC
— For differentiating between lobular and ductal cancer: 
E-cadherin
— For confirmation of neuroendocrine differentiation: 
chromogranin, synaptophysin, CD56
— For confirmation of presence of isolated cancer cells in 
sentinel lymph node: CK19
—  Markers of predictive and prognostic factors — Oestrogen receptor (ER): …….%
— Progesterone receptors (PgR): …….%
— HER2/Neu IHC; HER2/Neu FISH: (0–3) +
— Ki67 …….%
—  Biological subtypes of infiltrating breast cancer 
 (for cancer without special type and lobular type)
Luminal A
Luminal B (HER2-negative)
Luminal B (HER2-positive)
HER2-positive (non-luminal)
Triple negative (ductal)
—  Biological subtypes of infiltrating breast cancer 
 (special types of breast cancer)
Hormone-dependent
Hormone-independent
Referring physician’s personal data First name and surname; PWZ number
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B.1. Primary breast conserving 
treatment with no neoadjuvant 
systemic treatment
Janusz Piekarski, Arkadiusz Jeziorski
 — In patients with breast cancer in stage I and II 
(TNM UICC/AJCC 2010), conserving treatment 
(tumour excision and radiotherapy) is as efficient 
as mastectomy.
 — Breast conserving treatment (BCT) is the recom-
mended method of the treatment of breast cancer 
patients in stage I and II (TNM UICC/AJCC 2010).
 — Conserving treatment is possible in patients, in which 
conserving operation still allow performing a radi-
cal mastectomy.
 — Conserving treatment is possible in patients in whom 
primary tumour volume to breast volume ratio allows 
good cosmetic effect.
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B. PRIMARY SURGICAL TREATMENT  
OF INVASIVE BREAST CANCER
Subject Primary breast 
conserving treatment 
(BCT)
Analysed problems PSSO recommendation 
Indications to BCT
Patients with breast cancer in stage I and II are qualified to BCT (TNM UICC/AJCC 2010) 2+ 
Conserving treatment (tumour excision and radiotherapy) is as efficient as mastectomy, so BCT is 
recommended as primary surgical treatment in stage I and II (TNM UICC/AJCC 2010)
2+
Breast cancer patients in whom radical mastectomy will be performed are qualified to BCT 2+
BCT is performed in patients in whom the volume of primary tumour to volume of breast ratio allows 
a good cosmetic effect
2+
Patients with multifocal cancer are qualified to conserving treatment, if radical excision, postoperative 
radiotherapy, as well as good cosmetic effect is possible
2+
Patients with multicentric cancer are qualified to conserving treatment, if radical excision, 
postoperative radiotherapy, as well as good cosmetic effect is possible
2+
Absolute contraindications to BCT
Lack of patient consent for conserving treatment 2+
Lack of possibility of radical excision of breast cancer 2+
Lack of possibility of using supplemental radiotherapy 2+
Local recurrence after BCT is not a contraindication to repeated conserving treatment 0
Technical aspects of surgical operation
Radical excision of primary tumour is essential (R0 — this is an efficient surgical margin,  
so-called “no ink on the tumour”)
2+
When excision is not radical, excision margin should be widened or mastectomy performed 2+
In cases when intraoperative imaging shows that the lesion was not removed or not removed 
radically, excision of the appropriate lesion or its lacking part during the same operation is needed,  
as well as repeated intraoperative imaging
2+
In patients with non-palpable during physical examination cancer preoperative tumour localisation 
should be marked (metal marker, radioactive marker, “hook”). Optionally, excision under 
intraoperative USG control could be performed
2+
cont. Æ
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B.2. Primary mastectomy
Arkadiusz Jeziorski, Janusz Piekarski
 — According to its efficacy and results (loco-regional 
control and survival) BCT replaced mastectomy in 
the vast majority of breast cancer patients; however, 
some patients still have the indications to perform 
this operation, and some of them would prefer this 
way of treatment.
 — Mastectomy remains the standard of breast cancer 
treatment in a selected group of patients.
 — Patients with infiltrating breast cancer stage I and II, 
who are ineligible to conserving treatment or who do 
not consent, are qualified to mastectomy.
 — Depending on clinical indications the are following 
types of mastectomy:
Nipple sparing mastectomy (NSM) — amputation cov-
ers breast gland together with fascia of pectoral major mus-
cle; skin covering of breast gland, nipple-areola complex 
(NAC), and pectoral muscles: major and minor are left.
Skin sparing mastectomy (SSM) — amputation 
covers breast gland, part of the skin covering gland 
together with nipple-areola complex together with 
fascia of pectoral major muscle; significant part of skin 
covering breast gland and pectoral muscles; major and 
minor are left.
Simple mastectomy — removal of whole breast 
together with skin covering the gland, nipple-areola 
complex, and fascia of muscle pectoral major, without 
axillary lymph nodes.
Madden modified radical mastectomy — removing 
the whole breast together with the skin covering the 
gland, nipple-areola complex, and fascia of pectoral 
major muscle and excision of axillary lymph nodes.
Patey modified radical mastectomy — removal of 
whole breast together with the skin covering the gland, 
nipple-areola complex, and fascia of pectoral major 
muscle and excision of pectoral muscle minor together 
with axillary lymphadenectomy.
Radical mastectomy — removal of whole breast 
together with the skin covering the gland, nipple-areola 
complex, and both pectoral muscles and axillary lym-
phadenectomy, with lymph nodes level I–III.
References
1. Fisher B, Anderson S, Bryant J et al. Twenty-year followup of a rando-
mized trial comparing total mastectomy, lumpectomy, and lumpectomy 
plus irradiation for the treatment of invasive breast cancer. N Engl J 
Med 2002; 347: 1233–1241.
2. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a ran-
domized study comparing breast-conserving surgery with radical ma-
stectomy for early breast cancer. N Engl J Med 2002; 347: 1227–1232.
3. Blichert-Toft M, Nielsen M, Düring M. Long-term results of breast 
conserving surgery vs. Mastectomy for early stage invasive breast 
cancer: 20-year follow-up of the Danish randomized DBCG-82TM 
protocol. Acta Oncol 2008; 47: 672–681.
4. Johansen H, Kaae S, Jensen MB, Mouridsen HAT. Extended radical 
mastectomy versus simple mastectomy followed by radiotherapy in 
primary breast cancer. A fifty-year follow-up to the Copenhagen Breast 
Cancer randomised study. Acta Oncol 2008; 47: 633–638.
Analysed problems PSSO recommendation 
Intraoperative marking of excised preparation directions is essential (e.g. with strands, metal markers, 
etc.). It enables precise indication of places/locations of lack of radical operations (lack of R0 margin)
2+
It is recommended that intraoperative imaging (mammography/USG) excised preparation is 
performed in order to confirm radical excision of appropriate lesion
2+
Intraoperative imaging is performed with the same method, which was used for preoperative lesion 
identification
2+
Site after excised tumour must be marked with metal “clips” in order to improve accuracy of 
supplemental adjuvant radiotherapy (“clips” made of material enabling performance of MRI in 
the future)
2+
It is recommended to set five “clips” on the site wall (from lateral, medial, distal, and proximal sides) 
and its fundus (in the deepest place)
2+
Intraoperative histological analysis of excision margins is not a standard in BCT 2+
In each case BCT of invasive cancer in step II irradiation of whole breast is performed 2+
Each patient after mastectomy needs the assessment of MDT to establish optimal adjuvant therapy 2+
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Subject Primary mastectomy
Analysed problems PSSO recommendation 
As efficacy and treatment result (loco-regional disease control, and survival) of BCT are comparable, 
it could replace mastectomy in the vast majority of breast cancer patients
2+
Diagnosis
Similarly to all cases qualified to surgical operation, according to the standard, it includes: physical 
examination, imaging (MMR, USG), and histological evaluation (CB)
2+
Indications to mastectomy
Patient’s choice and decision 2+
Each cancer in stage I and II ineligible to BCT
Radical cancer excision margins impossible to achieve (lack of R0 margins), also after re-operation 2+
Too large tumour in relation to breast and poor cosmetic effect expected (tumour/breast ratio) 2+
Inflammatory breast cancer as an option after NAC 2+
Early period of pregnancy (I trimester) 1+
No response to systemic neoadjuvant treatment 2+
In patients with DCIS:
— extensive, palpable tumour (unfavourable tumour/breast ratio)
— high VNPI index (≥ 10)
2+
2+
In case of contraindications to postoperative radiotherapy after BCT (or BCT impossible to perform) 2+
Palliative, salvage mastectomy 2+
Patients at high and very high risk with confirmed genetic changes or with positive family history of 
breast cancer
0
Indications to particular types of mastectomy
NSM/SSM
Patients at high and very high risk with confirmed genetic changes or with positive family history of 
breast cancer, qualified to surgical procedures, reducing the risk of morbidity
1+
Patients with preoperatively diagnosed DCIS, ineligible to BCT 2+
In case of extensive ductal hyperplasia or lobular hyperplasia with atypical cells 0
Simple mastectomy
Patients with DCIS, ineligible to BCT 2+
Patients with invasive breast cancer, ineligible to BCT, without axillar lymphadenectomy  
(SLN without metastases)
2+
Patients who have undergone palliative mastectomy due to locally advanced breast cancer 2+
Patey modified radical mastectomy
In patients with intraoperative diagnosed Rotter’s lymph node infiltration into pectoral minor 
muscle
2+
Radical mastectomy
In patients with cancer infiltration of pectoral major muscle, with partial or radical excision of 
pectoral major muscle, also after systemic neoadjuvant treatment
2+
Madden modified radical mastectomy
In remaining, not aforementioned cases, with no contraindications to BCT 2+
Each patient after mastectomy requires MDT assessment to determine optimal adjuvant treatment 
— indications to XRT and systemic treatment
2+
Each patient qualified to mastectomy should receive a comprehensive information regarding 
possibility of reconstructive operation as well as to receive breast prosthesis
2+
Each patient after mastectomy requires rehabilitation to prevent extremity oedema and recover 
appropriate physical functions
2+
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B.3. Sentinel lymph node biopsy 
in primary breast cancer (with no 
neoadjuvant systemic treatment)
Zbigniew I. Nowecki, Arkadiusz Jeziorski,  
Dawid Murawa
 — Sentinel lymph node biopsy (SLNB) in breast cancer 
is a reliable method to assess cancer stage in regional 
lymph nodes.
 — Indications to SLNB include clinically unchanged 
lymph nodes (cN0), confirmed in USG and cyto-
logical analysis after PCI (in case of indications 
to biopsy).
 — To identify SLN an isotope-based technique is used 
+/– SLN staining. Sampling ≥ 4 SLN does not im-
prove the accuracy of this method.
 — Intraoperative SLN is not a standard of care dur-
ing SLNB.
 — Clinics (operational wards) that do not perform SLNB 
in breast cancer should not treat this type of patient.
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Subject Indications to sentinel 
lymph node biopsy 
in early stage breast 
cancer (with no systemic 
neoadjuvant treatment)
Analysed problems PSSO recommendation 
SLNB is performed according to PSSO recommendation 2+
SLNB is performed to make appropriate assessment of breast cancer stage in regional lymph nodes 2+
Indications to SLNB
Clinically unchanged lymph nodes (cN0) confirmed in USG and (in case of indications to biopsy) 2+
Cancer cT 1-2 2+
Cancer cT 3 1+
Cancer cT4 a-c 0
Multifocal/multicentre cancer 2+
Inflammatory breast cancer 2–
Breast sarcoma 2–
Breast lymphoma 2–
Phyllodes tumour 2–
Metastases of malignant cancer from localisation other than breast 2–
In DCIS
Palpable tumour  2+
Microcalcifications ≥ 5 cm; microcalcifications ≥ 2 cm with poor risk factors 2+
Suspicious for microinvasion 2+
Eligible to mastectomy 2+
After previous excision of invasive and/or preinvasive cancer (together with excision of cancer site 
without widening the surgical margins — depending on surgical margins during primary excision)
2+
After previous plastic surgery of breast (e.g. reduction mammoplasty) 1+
Cancer recurrence after BCT from SLNB 2+
SLNB in area of internal mammary artery confluence 2–
During “prophylactic mastectomy” 2–
Pregnant women (administration of isotope and biopsy on the same day),  
SLNB without dye deposition
1+
Breastfeeding women 2+
cont. Æ
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B.4. Lymphadenectomy in primary 
breast cancer (with no neoadjuvant 
systemic treatment)
Zbigniew I. Nowecki, Arkadiusz Jeziorski
 — Patients qualified to initial surgical treatment of 
breast cancer with confirmed metastases to lymph 
nodes (pN+) require lymphadenectomy in area of 
regional lymphatic confluence (axillary lymph node 
dissection, ALND).
 — ALND enables the assessment of breast cancer stage 
and regional disease control. This surgical procedure 
does not influence patient’s survival.
 — Each patient qualified initially to ALND requires 
preoperative USG of regional confluence with 
confirmation of metastases to lymph nodes by using 
fine-needle biopsy (FNB) (NCCN2.2016).
 — In case of negative verification of FNB the patients 
should be qualified to SLNB (unless there are clear 
contraindications: very early pregnancy, no patient’s 
consent, etc.).
 — Each patient initially qualified to ALND, should 
be presented to MDT after receiving postoperative 
pathology report to qualify to appropriate adju-
vant treatment.
 — Each patient after ALND requires rehabilitation 
and prevention of oedemas.
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Analysed problems PSSO recommendation 
Elderly patients 2+
Male patients with breast cancer 2+
Method of SLNB according to PSSO recommendations
SLNB performed in standard way by all — surgical team members 2+
Radiocolloid administered the day before or on the day of operation (minimally four hours 
before operation)
2+
Isotope: colloid 99mTc 2+
Dye: PatentBlau 2–
Triple method 2+
Method with ferromagnetism 1+
Method with indocyanine green 0
Clinical intraoperative assessment of axilla after — SLN biopsy 2+
Localisation of marker (isotope +/– dye)
SLNB performed according to PSSO recommendations
Standardised method, performed by all members of the surgical team  
(possible injection of isotope or dye: peritumoural, into tumour, intracutaneous, subcutaneous)
2+
Number of sampled SLN
Sampling ≥ 4 SLN does not improve test accuracy 2+
Level of SLN identification should be at the level ≥ 95% 2+
Intraoperative assessment of SLN:
in BCT (meeting the criteria of Z0011 Trial) 2–
in BCT (not meeting the criteria of Z0011 Trial) 1–
in mastectomy 1–
Each patient with diagnosed metastasis (each metastasis) to regional  
lymph nodes should be discussed by MDT to identify optimal adjuvant treatment
2+
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Subject Indications to axillar 
lymphadenectomy in early stage 
breast cancer (with no systemic 
neoadjuvant treatment)
Analysed problems PSSO recommendation
ALND is performed to improve patient survival 2–
ALND is one of the options to achieve appropriate regional disease control 1+
Lymphadenectomy should be limited to ALND 2+
ALND includes dissection of lymph nodes from level I/II 2+
ALND includes dissection of lymph nodes from level III only in the case of clinically suspicious 
lymph nodes of level II
2+
Indications to ALND
Metastases to regional lymph nodes, when systemic neoadjuvant treatment is not expected
cN1 (confirmed by using USG + PCI) 2+
cN2 (confirmed by using USG + PCI) 2+
cN3 (confirmed by using USG + PCI) 2–
“Occult” breast cancer  2+
Surgical operation of breast with DCIS diagnosed 2–
Lymph nodes recurrence after previous treatment of breast cancer 2+
In breast sarcomas, lymphomas, and tumour phyllodes (with exclusion of cases with 
confirmed metastases)
2–
Inadequate ALND in cases of suspected lack of radicality (e.g. < 10 lymph nodes in 
preoperative histological preparation, others)
2–
Even if possible SLNB 2–
Indications to ALND after SLNB
Lack of SLN identification during SLNB (level I of axillary lymph nodes is dissected) 2+
SLN + with extracapsular lymph node infiltration 1+
SLN (i+) and BCT 2–
SLN (mic+) and BCT 2–
SLN+ (met criteria of Z0011 Trial) 1–
SLN+ and mastectomy (without chest wall irradiation) 2+
SLN+ and mastectomy (with chest wall irradiation) and only in cases: T1/2, SLN 1–2(+), 
without infiltration of lymph node capsule
0
Each patient with diagnosed metastasis (each metastasis) to regional lymph nodes should 
be discussed by MDT to identify optimal adjuvant treatment
2+
Each patient after ALND requires rehabilitation to prevent oedemas and recover appropriate 
physical function
2+
B.5. Intraoperative radiotherapy
Dawid Murawa, Bartosz Urbański
 — Radiotherapy is used in breast conserving treatment 
and during mastectomy with coexisting specific risk 
factors. Individualisation of radiotherapy during 
planning and delivery of the beam should be high-
lighted.
 — Irradiation boost of tumour site during BCT could be 
also performed using electrons, photons, and brachy-
therapy.
 — Whole-breast irradiation changes recurrence risk 
and influences patients’ overall survival.
 — The doses during whole-breast irradiation should 
range between 46 and 50 Gy in 23–25 fractions or 
40 and 42.5 Gy in 15–16 fractions (hypofractiona-
tion). In patients with high recurrence risk, irradia-
tion boost of the tumour site is recommended. The 
usual recommended dose ranges between 10 and 
16 Gy in 4–8 fractions.
 — In case of accelerated partial breast irradiation, 
(APBI) patient participation in clinical trials is rec-
ommended.
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Subject Intraoperative 
radiotherapy
Analysed problems PSSO recommendation
MDT decision, suggested standpoint of surgical oncologist
Irradiation boost of tumour site (local control improvement, without influence of survival):
Age < 40 years
Age 40–60 years
Age > 60 years, G3, or > pT1
2+
1+
0
Intraoperative radiotherapy (including APBI)*:
As irradiation boost before whole-breast irradiation 
As the only method of breast irradiation (IORT 50kV, IOERT)**
— > 50 years**
— > 70 years**
2+
0
0
Postoperative partial breast irradiation as the only method of radiotherapy:
Intra-tissue brachytherapy
— > 70 years**
• Intra-cavity brachytherapy (balloon brachytherapy)
0
0
1–
*Recommended participation on available clinical trials; **only tumours pT1, pN0, R0, G1-G2, HR+, non-lobular, age > 50 years, with no extensive intraductal 
component, IORT during initial surgical operation
 — Preliminary studies with APBI show that local con-
trol of early breast cancer (with specific inclusion 
criteria) is comparable with standard treatment using 
whole-breast irradiation.
 — In case of unavailable clinical trials, use of APBI 
could be based on ASTRO/GEC-ESTRO guidelines; 
patient’s age > 50 years, with no BRCA1/BRCA2 mu-
tations, T1N0 ER positive breast cancer, infiltrating 
ductal with no extensive intraductal component and 
LCIS, negative surgical margins.
References
1. http://www.ago-online.de/en/guidelines-mamma/march-2016.
2. https://www.nccn.org/professionals/physician_gls/f_guidelines.
asp#site.
3. Sedlmayer F, Sautter-Bihl M-L, Budach W et al. and Breast Cancer 
Expert Panel of the German Society of Radiation Oncology (DEGRO). 
DEGRO practical guidelines: radiotherapy of breast cancer IDEGRO 
practical guidelines: radiotherapy of breast cancer I. Radiotherapy 
following breast conserving therapy for invasive breast cancer. Strah-
lenther Onkol 2013; 189: 825–833.
4. Wenz F, Sedlmayer F, Herskind C et al. Accelerated Partial Breast 
Irradiation in clinical practice. Breast Care (Basel) 2015; 10: 247–252.
100
OncOlOgy in clinical practice 2017, Vol. 13, No. 3
C.1. Breast conserving treatment after 
systemic neoadjuvant treatment
Wojciech M. Wysocki, Wojciech Polkowski,  
Andrzej Kurylcio
 — Method of choice of surgical treatment of breast can-
cer patients should be wide local excision WLE); it 
concerns also the patients in whom baseline primary 
cancer stage excluded BCT, providing satisfactory 
response to systemic neoadjuvant treatment.
 — In patients with breast cancer of size > 2 cm (ac-
cording to ESMO 2015 recommendation), espe-
cially in biological cancer subtypes of poor prognosis 
(HER2-positive, triple negative), systemic preopera-
tive treatment could be used, improving the condi-
tions to local operation and prognosis.
 — If patients could undergo BCT and express a wish 
to do so, and given that the centre has no capacity, 
the patient should be referred to a centre where this 
kind of treatment is possible.
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C. PRIMARY NEOADjUVANT TREATMENT
Subject Indications to breast 
conserving treatment after 
systemic neoadjuvant 
treatment
Analysed problems PSSO recommendation
In cases of primary large operable breast cancer, and the need to perform mastectomy together 
with anterograde and adjuvant treatment, if the patient expresses the wish to conserve the 
breast, systemic neoadjuvant treatment should be considered
2+
Before systemic neoadjuvant treatment, the marker should be placed in the localisation of the 
primary tumour
2+
Assessment of response to systemic neoadjuvant treatment should involve physical examination 
and radiological imaging
2+
To assess the response to systemic neoadjuvant treatment mammography and/or magnetic 
resonance imaging should be used
2+
The imaging method should be selected by MDT (considering, in the first place, the method 
that was used to assess the cancer size before systemic neoadjuvant treatment)
2+
Breast conserving surgical operation after systemic neoadjuvant treatment should be performed 
with dissection of the area indicated in controlled preoperative imaging
2+
Breast conserving surgical operation after systemic neoadjuvant treatment should be performed 
with achievement of cancer-free microscopic surgical excision margins (R0)
2+
Breast conserving surgical operation after systemic neoadjuvant treatment should be performed 
app. 2–4 weeks after the last cycle of this therapy (after nadir period)
2+
Indications
Confirmed patient’s consent for breast conserving treatment 2+
Achieving complete response after systemic neoadjuvant treatment 2+
Achieving partial response after systemic neoadjuvant treatment — enabling a therapy meeting 
criteria of conservative treatment and achieving good cosmetic effect
2+
Achieving partial response (with complete recovery of skin changes, in case of T4a-c tumour; 
after careful MDT assessment with individual recurrence risk analysis), conducting a therapy 
meeting criteria of conservative treatment and achieving good cosmetic effect
0
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C.2. Mastectomy after primary 
neoadjuvant treatment
Wojciech M. Wysocki, Wojciech Polkowski,  
Andrzej Kurylcio
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Subject Indications for 
mastectomy after 
primary neoadjuvant 
treatment
Analysed problems PSSO recommendation
Mastectomy after systemic neoadjuvant treatment should be performed approximately 2–4 weeks 
after the last cycle of this therapy (after nadir period)
2+
Indications
Withdrawal of patient’s consent for attempted breast conserving treatment 2+
Diagnosis of disease progression during systemic neoadjuvant treatment 2+
Achieving partial response after systemic neoadjuvant treatment with decreasing of tumour size, 
which DOES NOT ENABLE its wide dissection (despite possibly meeting other, usual criteria for BCS)
2+
Presence of cancer cells in surgical operation margins after attempt of repeated local dissection 2+
No possibility of using adjuvant radiotherapy 2+
In the case of achieving response to systemic neoadjuvant treatment, if inflammatory cancer was 
initially diagnosed
2+
In the case of achieving response to systemic neoadjuvant treatment, if multicentre lesions were 
initially diagnosed
2+
In the case of achieving response to systemic neoadjuvant treatment, if cT4a-c cancer* was initially 
diagnosed
2+
*Except reservation according to NCCN 2.2016 presented in the table of indications to breast conserving treatment after systemic neoadjuvant treatment
C.3. Sentinel lymph node biopsy 
in breast cancer patients after 
neoadjuvant treatment
Zbigniew I. Nowecki, Arkadiusz Jeziorski
 — Use of systemic neoadjuvant treatment (neoadjuvant 
chemotherapy, NAC, or endocrine therapy) enables 
downstaging of regional lymph nodes from pN+ to 
pN0 in 20–40% of treated patients.
 — Sentinel lymph node biopsy in breast cancer patients 
eligible to NAC replaces standard method ALND.
 — Indications to perform SLNB include clinically 
unchanged lymph nodes (cN0) confirmed by USG.
 — Isotope and staining methods are used in identifica-
tion of SLN.
 — Intraoperative assessment of SLN is recommended 
during SLNB after NAC.
 — It is recommended that SLNB after NAC is per-
formed by centres/teams with extensive experience 
of SLNB.
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Subject Indications to sentinel lymph node biopsy 
after systemic neoadjuvant treatment
Analysed problems PSSO recommendation
SLNB is performed to appropriately assess cancer stage in regional lymph 
nodes
2+
A. Regional lymph node states before NAC — cN0
Indications to SLNB in patients initially with cN0
SLNB before NAC 1+
SLNB after NAC 0
Repeat SLNB after NAC, if SLNB before NAC detected metastases to SLN 2–
Methods of SLN assessment in patients initially with cN0
SLNB before NAC:
Standard method for the centre, according to PSSO recommendations for SLNB 2+
SLNB after NAC:
Standard method for the centre, according to PSSO recommendations for 
SLNB, but methods with the use of isotope and dye
2+
Localisation of marker placing (isotope +/– dye) in patients initially with cN0:
According to PSSO recommendations for SLNB, standard method for the centre 2+
Number of sampled SLNs in patients initially with cN0
According to PSSO recommendations for SLNB, standard method for the centre 2+
Intraoperative assessment of SLN in patients initially with cN0
SLNB before NAC — not required 2+
SLNB after NAC — indicated 1+
After NAC, postoperative assessment of SLN is recommended in order to 
identify each metastasis (including ITC and micrometastasis)
2+
Recommended surgical procedures in patients initially with cN0 after 
performing SLNB before NAC
Below are mentioned the situations with pN0 before NAC:
pN0 (SLN) before NAC, after NAC Proceeding — observation 2+
Below are mentioned the situations with pN+ before NAC:
pN+ (SLN) before NAC
ycN0 after NAC
(qualification similar to Z0011 Trial)
Proceeding — ALND 2+
Proceeding — observation 1–
Proceeding — repeat SLNB 2–
pN+ (SLN) before NAC
— ycN0 after NAC
(qualification does not meet criteria to Z0011 Trial)
Proceeding — ALND# 2+
Proceeding — radiotherapy 
of lymphatic confluence
2–
Proceeding — repeat SLNB 2–
Recommended surgical procedures in patients after performed SLNB 
after NAC
Surgical procedures in patients initially with cN0 and ycN0
ypN0 (SLN) — proceeding: observation (only SLNB performed) 1+
ypN+ (SLN) — proceeding: ALND 2+
B. Regional lymph node states before NAC — cN+
Surgical procedures in patients initially with cN+ before NAC
Administration of “marker” into metastatic lymph node is indicated when 
SLNB is considered after NAC in patients with pN+ before NAC
2+
Methods of indicate of SLN:
Triple method 2+
cont. Æ
103
Surgical management of breast malignancies
C.4. Lymphadenectomy in breast 
cancer after systemic neoadjuvant 
treatment
Zbigniew I. Nowecki, Dawid Murawa
 — The patients after neoadjuvant chemotherapy 
qualified for surgical treatment of breast cancer in 
cases of metastases to regional lymph nodes (pN+) 
require ALND.
 — Using of neoadjuvant chemotherapy in patients 
with locally advanced breast cancer enables radical 
operation. ALND is a method making it possible to 
achieve regional disease control. This type of opera-
tion has no influence on survival.
 — Achieving complete pathology regression (yp-
T0ypN0) after neoadjuvant chemotherapy improves 
survival in some of the biological subtypes of breast 
cancer (TNBC, HER2+). Thus, in patients who will 
require postoperative systemic chemotherapy, that 
treatment should be considered before operation. 
This also applies to the patients who require tumour 
“shrinkage” to perform BCT, as well as in patients 
with biological subtypes of poor prognosis, regardless 
of extension of planned operation.
 — Each patient after neoadjuvant chemotherapy 
eligible to ALND, after receiving a postoperative 
pathology report, should be discussed by the MDT 
regarding qualification to possible adjuvant treat-
ment.
 — Each patient after ALND requires rehabilitation 
and prevention of oedemas.
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Analysed problems PSSO recommendation
Injection of isotope + dye:
Standard method for the centre 2+
Number of sampled SLN:
Sampling of ≥ 3 SLN, if requirement not met, ALND should be performed 2+
Number of sampled SLN:
Sampling of ≥ 3 SLN and “marker”, if requirement not met, ALND should be 
performed
2+
Intraoperative assessment of SLN in patients initially with cN+ 
before NAC:
Indicated 2–
Each patient with diagnosed metastasis (each metastasis) to regional lymph 
nodes should be discussed by MDT to identify optimal adjuvant treatment
2+
Surgical procedures in patients initially with cN+ and ycN0 after NAC
Criteria of Z1071 Trial met: proceeding — only SLNB 0
Criteria of Z1071 Trial not met: proceeding — ALND 1+
Surgical procedures in patients initially with cN+ and ycN+ after NAC
Proceeding — ALND 2+
104
OncOlOgy in clinical practice 2017, Vol. 13, No. 3
Subject Indications to axillar 
lymphadenectomy after 
systemic neoadjuvant 
treatment
Analysed problems PSSO recommendation
If patients need systemic therapy (chemotherapy) based on preoperative MDT, initiation of such 
treatment should be considered before surgery
2+
Administration of entire systemic neoadjuvant treatment before operation is standard 2+
Standard methods of assessing the response to NAC include:
Physical examination 2+
USG 2+
MRI 1+
Disease progression during NAC is an indication to “salvage” surgery or radiotherapy 2+
Surgical treatment is planned for the period 2–4 weeks after NAC completion (in order to avoid 
complications after chemotherapy)
2+
pN+ after NAC is an indication to ALND 2+
Each metastasis to SLN after NAC (including ITC and micrometastasis) is an indication to ALND 2+
In case of pN+ before NAC, the preferred method of surgical treatment is still ALND after NAC 
completion
 1+
Acceptable method of surgical treatment (unless assessed HP before NAC regional lymph nodes 
status) is ALND after NAC completion
1+
Lack of SLN identification after SLNB in patients treated with NAC is an indication to ALND 2+
Lack of identification of ≥ 3 SLN and/or lack of “clip” in sampled SLN after NAC in case of conversion 
from cN+ to cN0 is an indication to ALND
2+
Each patient with diagnosed metastasis to regional lymph nodes (each metastasis) should be 
discussed by MDT to identify optimal adjuvant treatment
2+
Each patient after ALND requires rehabilitation in order to prevent extremity of oedema and to 
recover appropriate physical function
2+
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Systemic preoperative treatment
Systemic preoperative treatment of breast cancer 
patients could be an initial method in the following situ-
ations:
 — locally advanced, primary inoperable (including 
inflammatory) breast cancer. Use of cytotoxic drugs 
alone or in combination with targeted therapy could 
downstage a tumour and make operation possible, 
decreasing the risk of micrometastases and improv-
ing long-term results,
 — downstaging is a decrease of loco-regional advance-
ment of primary inoperable breast cancer, to per-
form breast conserving surgical operation,
 — in breast cancer subtypes with especially poor prog-
nosis [e.g. TNBC and HER2(+)], regardless of initial 
advancement and the extension of planned surgical 
operations (especially in tumours > 2 cm). Achiev-
ing pCR (ypT0ypN0) in those subtypes improves 
long-term results and prolongs OS.
In patients who possibly require systemic preopera-
tive treatment MDT, based on breast cancer subtype 
and its advancement, should consider introducing this 
therapy before operation. It concerns the aforemen-
tioned situations regardless of the extension of planned 
surgical operations.
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Clinical Trial ACOSOG Z0011
Inclusion criteria:
 — female patients diagnosed with breast cancer 
cT1-2cN0 M0,
 — detection of macrometastases of breast cancer 
to ≤ 2 SLN, excluding patients with extranodal in-
filtrations (“gross extranodal disease”),
 — after BCT (radical conserving surgical operations 
and radiotherapy from tangential fields),
 — systemic adjuvant treatment according to postopera-
tive indications.
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Clinical Trial ACOSOG Z1071 (Alliance)
Inclusion criteria:
 — female patients with verified diagnosis of breast 
cancer and metastasis in lymph nodes verified after 
biopsy PCI/CB,
 — clinical stage cT1-2cN0 M0,
 — after neoadjuvant chemotherapy with effect cN0,
 — recommended triple method of SLNB (isotope and 
dye) with sampling of > 2 SLN.
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Editor’s notes to parts B.3, B.4, C.1, C.2, C.3, C.4
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D.1. Breast cysts
Janusz Piekarski, Arkadiusz Jeziorski
 — Breast cysts could be divided into:
•  simple/uncomplicated cysts, with thin wall and no 
echoes in USG,
•  complicated, with thin wall and homogenous hypo-
echoic content in USG,
•  complex, consisting of cystic and solid (thickened 
cyst walls, septa, and solid intracystic structures).
 — The method of choice during diagnosis of simple and 
complicated cysts (homogenous hypoechoic) as well 
as groups of microcysts is ultrasonography.
D. OTHER RECOMMENDATIONS
Subject Breast cysts
Analysed problems PSSO 
recommendation
The method of choice for cyst diagnosis is USG 2+
Simple cysts are classified as BIRADS 2 (benign lesion). In cases without clinical symptoms there are no 
indications for biopsy of simple cysts
2+
Aspiration biopsy of a simple cyst could be performed in the case of clinical signs and symptoms 1+
After aspiration biopsy of a simple cyst there are no indications for cytological assessment of aspirated 
mass due to the extremely low possibility of diagnosing cancer in this cyst. Exceptional situations 
include cases when the aspirated mass is bloody coloured
1+
Complicated cysts and groups of microcysts are classified as BIRADS 3 (possibly benign lesions). 
Ultrasound follow-up or fine-needle aspiration (FNA) is recommended in six months
2+
When a complex cyst is visible in ultrasound — BIRADS 4 (suspicious lesion) — possible diagnosis 
should be confirmed after biopsy with histological evaluation. Whenever possible, histological 
assessment of a sample from a solid part of the complex cyst should be performed
2+
D.2. Fibroadenoma
Janusz Piekarski, Arkadiusz Jeziorski
 — Fibroadenomas are the most commonly diagnosed 
benign breast tumours, most prevalent in young 
women, usually with size 2–3 cm. There are mainly 
single lesions; however, in some patients the ten-
dency is observed toward multiple lesions of dif-
ferent sizes.
 — Once diagnosis of fibroadenoma is established, there 
is no need for excision of the lesion or for further 
diagnostics workup.
Subject Fibroadenomas
Analysed problems PSSO recommendation
Considerable diagnosis of fibroadenoma based on ultrasound is possible only if the lesion  
meets the following criteria:
 —   is homogenous
 —   is solid
 —   is oval
 —   its long axis is parallel to the surface of the skin
Such lesions are assigned with BIRADS 3 category (possibly benign lesion), and additionally:
 —   either underwent observation (follow-up USG in six months)
 —   or biopsy
2+
Fibroadenomas not changed during observation are re-classified from BIRADS 3  
(possibly benign lesion) to BIRADS 2 category (benign lesion)
2+
cont. Æ
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D.3. Atypical ductal hyperplasia 
Piotr Gierej
 — Atypical ductal hyperplasia (ADH)/atypical intra-
ductal epithelial proliferation (AIDEP) is a factor 
increasing the risk of cancer development (3–5-fold) 
in the same or opposite breast and is considered as 
a precancerous condition. The risk of cancer devel-
opment as higher as number of ADH-type lesions 
is higher and younger patient’s age. The prospective 
predictive value for malignancy in resection (PPV) 
for ADH is 20–30%.
 — During histological diagnosis core-needle biop-
sy/Mammotome vacuum-assisted biopsy is recom-
mended.
 — In the case of ADH diagnosis, surgical biopsy proce-
dure (excisional biopsy) is basically recommended. 
Extensive/multifocal ADH is also a possible indica-
tion to mastectomy. The risk of cancer diagnosis after 
ADH excisional biopsy is higher when histological 
evaluation reveals high levels of atypical cytology, 
necrosis, or/and the terminal ductal-lobular unit 
(TDLU) is more than 2.
 — When ADH is diagnosed within histological surgical 
margins after excision of invasive or pre-invasive 
cancer, radical surgical treatment (additional mar-
gins excision) could be retreated, especially when 
radiotherapy is planned. ADH does not increase the 
risk of local recurrence after radiotherapy.
 — When ADH is diagnosed within margins of a his-
tological sample after excision a radical surgical 
procedure (additional margins excision) is recom-
mended; the only observation could be allowed if 
there is complete excision in radiological evaluation.
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Analysed problems PSSO recommendation
When a lesion that is visible in USG does not show all features of fibroadenoma it should be 
assigned with BIRADS 4 category (suspicious lesion). In this case core-needle biopsy is needed
2+
In patients with multiple fibroadenomas sufficient procedures include a biopsy (fine- or core-needle) 
of one of the lesions and follow-up ultrasound of the remaining lesions in six months
1+
If a diagnosed lesion:
 —   has the largest dimension greater than 3 cm
 —   has a cystic component
 —   or during six months its size increases by more than 1 cm
 —   phyllodes tumour (PT) should be suspected. Histological assessment should be performed  
  (core-needle biopsy)
2+
Diagnostic and therapeutic processes should be conducted regardless of whether the lesion  
is palpable or not
2+
If during the diagnostics procedure fibroadenoma is confirmed, there is no need for excision  
of the lesion
1+
Subject Atypical ductal 
hyperplasia
Analysed problems PSSO recommendation
Diagnosis of ADH in core-needle biopsy/Mammotome vacuum-assisted biopsy is a recommendation 
to open biopsy (excisional)
2+
Surgical treatment after diagnosis of ADH in core-needle biopsy/Mammotome vacuum-assisted 
biopsy could be exceptionally retreated when the following criteria are met:
 —   lack of tumour features in radiological imaging
 —   small size (≤ 2 TDLU in Mammotome vacuum-assisted biopsy)
 —   complete lesion excision during biopsy detected in follow-up radiological evaluation
0
When ADH is diagnosed within histological surgical margins after excision of invasive or pre-invasive 
cancer a radical surgical treatment is not needed
1+
cont. Æ
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D.4. Flat epithelial atypia
Piotr Gierej
 — Flat epithelial atypia (FEA)/columnar cell hyper-
plasia with atypia in radiological imaging most 
commonly co-exists with microcalcifications. FEA 
increases approximately five-fold the risk of breast 
cancer development. The predictive value for ma-
lignancy in resection for FEA is 0–10%.
 — During histological diagnosis core-needle biop-
sy/Mammotome vacuum-assisted biopsy is recom-
mended.
 — When FEA is diagnosed in biopsy, surgical treatment 
(excisional biopsy) is recommended.
 — When FEA is diagnosed within histological surgical 
margins after excision of invasive or pre-invasive 
cancer radical surgical treatment (additional mar-
gins excision) could be retreated, especially when 
supplemental radiotherapy is planned.
 — When FEA is diagnosed within margins of a histolog-
ical sample after excisional biopsy a radical surgical 
procedure is not needed, when microcalcifications 
have been completely dissected.
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When ADH is diagnosed within margins of a histological sample after excision a radical surgical 
procedure (additional margins excision) is recommended; the only observation could be 
exceptionally allowed if there is complete excision in radiological evaluation
0
Women with ADH should be informed about increased risk of breast cancer morbidity  2+
Mammography once per year is recommended as a follow-up 2+
MDT decision, the suggested standpoint of the surgical oncologist
Preventive endocrine therapy could be considered in female patients diagnosed with ADH, with high 
risk of breast cancer morbidity, but without a higher risk of thromboembolic complications
1+
Tamoxiphen given preventively in women with ADH at age over 35 years decreases the risk of breast 
cancer and DCIS morbidity
1+
Preventive administration of aromatase inhibitors (exemestane, anastrozole) in postmenopausal 
women is not recommended
0
Subject Flat epithelial atypia
Analysed problems PSSO recommendation
Surgical treatment after diagnosis of FEA in core-needle biopsy/Mammotome vacuum-assisted biopsy 
could be retreated when the following criteria are met:
 —   small size of FEA (≤ 2 TDLU in Mammotome vacuum-assisted biopsy)
 —   complete excision of the lesion during biopsy detected in follow-up radiological evaluation
1+
When FEA is diagnosed within histological surgical margins after excision of invasive or pre-invasive 
cancer, radical surgical treatment is not needed
0
When FEA is diagnosed within margins of histological sample after excisional biopsy, a radical surgical 
procedure is not recommended, when microcalcifications have been completely dissected
1+
Mammography once per year as population-based screening is recommended as a follow-up after 
FEA excision
2+
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D.5. Radial scar/complex sclerosing 
lesion (CSL)
Piotr Gierej
 — Radial scar/complex sclerosing lesion (CSL) is 
a benign lesion; however, the prospective predictive 
value for malignancy in resection is 8.3% (0–10%).
 — For histological diagnosis core-needle biopsy/Mam-
motome vacuum-assisted biopsy is recommended.
 — In case of radial scar/complex sclerosing lesion 
diagnosed in core-needle biopsy an open surgical 
biopsy procedure (excisional biopsy) is recom-
mended. Excisional biopsy could be retreated in the 
case of small lesions after excision in radiological 
follow-up after core-needle biopsy/Mammotome 
vacuum-assisted biopsy.
 — When radial scar/CSL is diagnosed within histologi-
cal surgical margins after excision, radical surgical 
treatment is not needed.
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Subject Radial scar/complex 
sclerosing lesion (CSL)
Analysed problems PSSO recommendation
In the case of small lesions and their completed dissection during core-needle biopsy/ 
/Mammotome vacuum-assisted biopsy, an open surgical biopsy procedure could be retreated
1+
When radial scar/CSL is diagnosed within histological surgical margins after excision, a radical 
surgical treatment is not needed
2+
The follow-up after dissection of radial scar/CSL could be performed within screening tests 1+
D.6. Papilloma
Piotr Gierej
 — Papilloma could co-exist with preinvasive and inva-
sive cancer (0–10%; for atypical papilloma — up to 
20%). Diagnosis atypical papilloma increases the risk 
of cancer development in the same breast (4.6–13%).
 — Core-needle biopsy/Mammotome vacuum-assisted 
biopsy is recommended for histological diagnosis.
 — Papilloma without atypical features in representative 
biopsy sample and correlation with imaging tests 
could undergo observation.
 — When atypical papilloma is diagnosed, a surgical 
treatment (excisional biopsy) is required. When 
atypical papilloma is diagnosed within histological 
surgical margins after excision, a radical surgical 
procedure is recommended, unless the lesion was 
completely dissected in radiological imaging.
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Subject Papilloma
Analysed problems PSSO recommendation
Diagnosis of atypical papilloma in core-needle biopsy/Mammotome vacuum-assisted biopsy is an 
indication to open (excisional) biopsy
 2+
When atypical papilloma is diagnosed within histological surgical margins after excision, a radical 
surgical procedure is recommended, unless the lesion was completely dissected in radiological 
imaging
2+
Multifocal papilloma requires open biopsy 2+
In patients with atypical papilloma, mammography once per year is recommended as a follow-up, 
and after excision of papilloma without atypical features — only screening tests
2+
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D.7. Diagnosis and treatment of ductal 
carcinoma in situ (DCIS) in the breast
Jacek Piechocki
 — Surgical treatment (BCT or mastectomy) is the 
basis of therapy of ductal carcinoma in situ (DCIS) 
in the breast.
 — Adjuvant treatment (radiotherapy, endocrine 
therapy) is discussed within MDT and together with 
the patient, to limit the recurrence risk.
 — Prognosis of relapses of invasive cancer after treat-
ment of DCIS is approximately 50% for all relapses 
after DCIS treatment.
Subject DCIS
Analysed problems PSSO recommendation
Diagnosis
Physical examination 2+
Mammography 2+
MMG targeted to MC 2+
Advantage of digital over analogue MMG 2+
Marker/clip inserted during core-needle biopsy 2+
USG of the breast 2+
MRI of breast for analysis of DCIS extension 0
Stereotactic biopsy/VAB 2+
PCI 2–
Surgical management
Surgical dissection after localisation 2+
Surgical dissection after “buckle”# localisation of extensive lesions 1+
Intraoperative MMG/RTG of preparation 2+
Intraoperative USG 0
Parallel extension of margins with their absence after MMG/RTG of preparation 2+
Intraoperative histological evaluation 2–
Excision with margin — R0 (“clear margin”) 2+
In multifocal DCIS — BCS possible to perform 0
Additional excision of margins, if in HP < 2 mm 1–
Mastectomy, if lack of negative margins after additional excision 2+
Mastectomy, if microcalcifications > 5 cm, even if possible to perform BCS 0
Indications to SLNB in DCIS after CB
BCS + SLNB (SLNB to consider in case of “poor prognosis factors” 2+
SLNB + mastectomy 2+
SLNB, when DCIS diagnosed in male patients 1+
ALND 2–
DCIS and microcalcifications > 5 cm, microcalcifications > 2 cm with poor prognosis factors 2+
Recurrences management
After radiotherapy — local dissection + SLNB 1+
Without radiotherapy — treatment like during initial diagnosis 2+
Adjuvant treatment after surgical management of DCIS
Adjuvant treatment is MDT decision, after analysis of recurrence risk; suggested standpoint of 
surgery oncologist in this situation:
DCIS with microinvasion in postoperative preparation evaluation — treatment like in invasive cancer 2+
Recommended radiotherapy
In every situation after BCS 0
cont. Æ
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D.8. Diagnosis and treatment of lobular 
carcinoma in situ
Leszek Kozłowski
 — Diagnosis of lesions in breast in patients with sus-
pected lobular carcinoma in situ (LCIS) should be 
based on histological evaluation after core-needle 
biopsy/Mammotome vacuum-assisted biopsy.
 — Histological diagnosis of LCIS should include 
histological subtypes according to tumour biology 
[lobular intraepithelial neoplasia (LIN)]: 1 — classi-
cal type, 2 — comedo necrosis type, 3 — floryd LIN, 
4 — pleomorphic type.
 — Diagnosis of LCIS increases the risk of breast cancer 
morbidity (at least 3.5-fold).
 — Extension of surgical operation in LCIS depends on 
the size of lesion in the breast and histological subtype.
 — Management in the case of diagnosis of concomitant 
DCIS of infiltrating cancer in material removed from 
the breast should be the same as in ductal cancer 
(DCIS or invasive).
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Analysed problems PSSO recommendation
After BCS in case of Van Nuys Prognostic Index 7–9 1+
After mastectomy 2–
Recommended endocrine therapy
Tamoxifen (when ER not tested in the sample) 0
Tamoxifen, only if ER-positive 0
Aromatase inhibitors (postmenopausal), if ER-positive 0
Trastuzumab, only if HER2-positive 2–
Prognostic factors for local and regional recurrence in the case of DCIS considered during the decision regarding possible 
adjuvant treatment (“poor prognosis factors”)
Age, size of cancer lesion, clinically palpable tumour, ≥ NG2, comedo necrosis, margins of cancer resection, residual tumour or 
microcalcifications after dissection, focused cancer, architecture of lesion
#A few markers inserted around the tumour before operation
Subject Indications to surgical 
treatment of lobular 
carcinoma in situ (LCIS)
Analysed problems PSSO recommendation
Diagnosis of lesions in the breast in patients with suspected lobular carcinoma in situ (LCIS) 
should be based on histological evaluation with consideration of histological subtype LIN (after 
core-needle biopsy/Mammotome vacuum-assisted biopsy)
2+
Patients with diagnosed LCIS require precise diagnosis based on physical examination and imaging 
tests (mammography, USG of breast, MRI), enabling exact assessment of disease advancement
2+
Diagnosis in all young women (below 40 years of age) with LCIS should be based on 
mammography and MRI of the breast
1+
Open/excisional biopsy should always be performed in cases of pleomorphic, floryd, and 
comedo necrosis LIN subtype in histological evaluation, regardless of the lesion diameter
2+
Extension of surgical operation depends on the size of the pathological lesion in the breast. 
Lesions of LIN classical type:
• below 2.0 cm
• completely resected, confirmed in imaging test
 —   do not require more radical operation
1+
In the case of diagnosis within margins of histological preparation, the features of LIN are as follows:
 —   classical type
more radical operation (with margins extension) is not required
2+
cont. Æ
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D.9. Breast cancer in young women
Sylwia Grodecka-Gazdecka
 — Breast cancer patients below 35 years of age account 
for a small group of patients (7% of patients in 
developed countries are below 40 years of age), but 
therapeutic decisions should be made by MDT, with 
consideration of young age specificity, including:
• different cancer biology at young age,
• different endocrine status of young women,
• maintenance of fertility after breast cancer treat-
ment,
• problems regarding treatment of the breast can-
cer during pregnancy,
• indications to surgical operations decreasing the 
risk of breast cancer morbidity (there are no in-
dications to surgical treatment of opposite breast 
except in carriers of BRCA1 gene mutations).
 — Performing a quick test of BRCA1 gene mutation al-
lows a more precise therapeutic decision to be made.
 — Young age is an independent factor of the risk of local 
recurrence after breast cancer treatment, which needs 
carefully decision-making regarding local treatment.
 — There is no evidence supporting routine performing of 
MRI before operation in young breast cancer patients 
(indications to MRI are the same as in older women). 
MRI during follow-up after treatment of breast cancer 
patients below 35 years of age is reasonable.
 — Surgical treatment should not be fundamentally 
different than in the group of older patients, in 
favour of conserving treatment of the breast as well 
as lymph nodes.
 — Breast reconstruction at the same time ensured 
comparable benefits as regard to overall survival as 
mastectomy without reconstruction; however, indi-
cations should be discussed within MDT, especially 
considering postoperative radiotherapy.
 — In BRCA1/2 genes mutation carriers:
• breast cancer treatment should be led in highly 
specialised centres (tertiary care services),
• there is no evidence regarding the advantage of 
mastectomy over BCT, but the decision about 
BCT should be made more carefully, considering 
the patient’s motivation to conserve the breast,
• radiotherapy does not increase the toxicity of 
treatment of mutation carriers.
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Analysed problems PSSO recommendation
In the case of diagnosis within margins of histological preparation, the features of LIN are as follows:
 —   pleomorphic
 —   floryd
 —   comedo necrosis
more radical operation (with margins extension) is required
2+
In the case of detection of glandular breast tissue (lesions difficult for diagnosis), the following 
are impossible:
 —   precise diagnosis
 —   radical excision with good cosmetic effect according to lesion size
 —   detection in sample lesions with ADH features
 —   indicating positive family history of breast cancer
 —   detecting mutations, increasing the risk of breast cancer morbidity (BRCA1, BRCA2, CHEK, etc.)
NMS with reconstruction at the same time is recommended
1+
Each patient with concomitant DCIS and LCIS lesions requires optimal therapy and further 
management, as in DCIS
2+
Each patient with concomitant invasive cancer and LCIS requires optimal therapy and further 
management, as in invasive cancer, depending on the clinical stage
2+
The aim of surgical treatment of LCIS is prevention of overlooking concomitant types of breast 
infiltrating cancer
1+
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Subject Breast cancer  
in young women
Analysed problems PSSO recommendation
All treatment plans should be discussed during an MDT meeting before therapy initiation, with 
consideration to genetic predispositions, ensuring fertility and addressing problems of breast cancer 
treatment during pregnancy
2+
Young age as an independent decision-making factor is not an indication to more aggressive loco-
regional as well as systemic treatment
2+
Decision-making regarding extension of loco-regional treatment needs psychological support 1+
Performing a quick test of BRCA1 gene mutation allows making a more precise therapeutic decision 1+
Young age is not an indication to mastectomy reducing a risk (except BRCA1 gene mutation 
carriers) because it does not prolong overall survival
1+
In BRCA1 gene mutation carriers:
 —   breast cancer treatment should be led in highly specialised centres (tertiary care services)
 —   there is no evidence regarding the advantage of mastectomy over BCT, but the decision about  
  BCT should be made more carefully, considering the patient’s motivation to conserve the breast
 —   radiotherapy does not increase the toxicity of treatment of mutation carriers
2+
2+
2+
Diagnosis
Standard diagnosis considering cancer clinical stage 2+
Indications to preoperative mammography magnetic resonance are similar to those for elderly 
patients, but it is reasonable to perform this test in high-risk patients as well as patients after 
radiotherapy of the chest wall
1+
Surgical treatment
Surgical treatment should not differ fundamentally from that used in elderly patients, preferring 
conserving therapy
1+
The choice of surgical treatment method of invasive cancer stage I and II should be based on the 
individual patient´s decision (after exclusion contraindications) with agreement from the MDT
1+
Breast reconstruction at the same time ensures the same benefits according to survival time as 
mastectomy without reconstruction, but the indications should be discussed during the MDT 
meeting, specifically considering postoperative radiotherapy
1+
The surgery of axillar lymph nodes should not differ from the same procedures in elderly patients 2+
SLNB is a standard procedure for cN0 cancer 2+
Neo- and adjuvant treatment is a decision of the MDT, suggested standpoint of the 
surgical oncologist:
Each patient ineligible to primary conserving treatment should be proposed neoadjuvant 
chemotherapy, and the treatment should be led in a highly specialised centre or within clinical trials
2+
Indications to radiotherapy are the same as in elderly patients, with consideration of RT after 
mastectomy in young patients with high recurrence risk
2+
Patients should receive information about genetics and fertility ensuring counselling 1+
Patients should be informed that endocrine contraceptive drugs are contraindicated after breast 
cancer treatment
2+
Patients should be informed that premature menopause increases the risk of bone density loss, 
which requires monitoring and treatment
2+
Post-therapy observation and management
Post-therapy observation is the same as in elderly patients 2+
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D.10. Breast cancer in pregnant and 
breastfeeding women
Agnieszka Jagiełło-Gruszfeld, Piotr Gierej
 — Diagnosis in pregnant women with suspicion 
of breast cancer should be done depending on 
indications, as in non-pregnant women — with 
a special covering during the X-ray imaging, and 
with core-needle biopsy in order to make histology 
analysis of lesions in the breast.
 — Premature pregnancy termination does not change 
the women prognosis.
 — Childbirth should be done with time, iatrogenic 
prematurity should be avoided.
 — Surgical operations in pregnant women are per-
formed as in non-pregnant women.
 — After the first trimester, chemotherapy does not 
increase the number of defects in the foetus, but 
increases the risk of developmental delay, preterm 
labour, and intrauterine foetal death.
 — There is no data on the increased risk of develop-
ing cancer during lifetime in children after chemo-
therapy in pregnancy 
 — There are some contraindications during pregnancy: 
radiotherapy, endocrine therapy, targeted therapy 
(anti-HER2), and administration of bisphospho-
nates and denosumab.
 — The prognosis in pregnant women considering ap-
propriate treatment is similar to the risk in non-preg-
nant women at the same clinical stage, but pregnant 
women more frequently have higher clinical stage 
(because of delayed diagnosis).
 — All therapeutic decisions should be made with-
in MDT.
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Subject Breast cancer in 
pregnant and 
breastfeeding women
Analysed problems PSSO recommendation
Diagnosis
Diagnosis of breast and biopsy in pregnant women with suspicion of breast cancer should be the 
same as in non-pregnant women
2+
During histological diagnosis core-needle biopsy is recommended. During biopsy, the pathologist 
should be informed about pregnancy — physiological changes in the breast during pregnancy 
increase the number of false-positive results
2+
There is a lack of indications to replace classical mammography with MRI mammography 2+
Diagnosis to establish clinical stage: abdominal USG, chest X-ray, if necessary (with foetus 
protection), other imaging tests only if clearly indicated, bone scintigraphy — not recommended
2+
Panel of imaging tests in stage I — chest X-ray 1+
Panel of imaging tests in stage II — chest X-ray and abdominal USG 1+
Panel of imaging tests in stage II — spinal MRI due to suggestions of metastases, without clear 
clinical signs and symptoms
1–
MRI (without gadolinium), if other imaging tests inconclusive (unambiguous) or there is a suspicion 
(clinical signs and symptoms) of bone or brain metastases
1+
Panel of imaging tests in stage III — chest X-ray and abdominal USG 1+
Ultrasound is the preferred test to assess breast, abdominal cavity, and pelvis 2+
Chest X-ray and mammography — with protective shield, is a safe management 1+
CT, PET, and bone scintigraphy are contraindicated 2+
Tests of markers: Ca 125, Ca 15-3 is not recommended 2+
Surgery treatment
Surgical operations in pregnant women are performed as in non-pregnant women 2+
cont. Æ
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Analysed problems PSSO recommendation
During the first trimester, mastectomy + SLNB/lymphadenectomy are recommended. Conserving 
treatment could be performed during the second and third trimester, when the expected time of 
radiotherapy initiation is after delivery term
1+
During pregnancy ≥ 23 weeks, surgical treatment should be performed in a centre with neonatal 
and obstetric protection
2+
Safety of parallel reconstruction operations during pregnancy is not clearly established and cannot 
be routinely recommended
0
SLNB
Pregnant women (isotope administration and biopsy on the same day) SLNB without dye 
administration
1+
Breastfeeding women 2+
Neo- and adjuvant treatment is a decision of the MDT, suggested standpoint of the 
surgical oncologist:
During pregnancy contraindicated are as follows:
 —   radiotherapy
 —   endocrine therapy
 —   targeted therapy (anti-HER2)
 —   bisphosphonates and denosumab
2+
Radiotherapy
Radiotherapy during pregnancy — contraindicated 2+
In pregnant women, planned radiotherapy postponement (if the patient does not receive 
chemotherapy) should not exceed 12 weeks
2+
Systemic treatment
Endocrine therapy, targeted therapy (anti-HER2), and bisphosphonates and denosumab  
—  contraindicated
2+
Chemotherapy during the first trimester is contraindicated. Chemotherapy could be used during 
the second and third trimesters, and indications are the same as in non-pregnant women (allowed 
drugs: anthracyclines and taxanes)
2+
Childbirth/pregnancy termination is a decision of the MDT, suggested standpoint of the 
surgical oncologist
Childbirth should be done with time; iatrogenic prematurity should be avoided 2+
Premature pregnancy termination does not change the mother’s prognosis 1+
Natural childbirth/caesarean section as in healthy women, childbirth ≤ 3 weeks after last 
chemotherapy administration should be avoided
1+
The patient should be informed that breastfeeding is contraindicated during radiotherapy, 
chemotherapy, and endocrine therapy
2+
DCIS in pregnant women
DCIS diagnosed in pregnant women requires surgical treatment, as in non-pregnant women 2+
The principles of surgical treatment of DCIS in pregnant women are the same as in non-pregnant 
women
2+
Observation of DCIS is allowed only during the last trimester 2+
Radiotherapy after BCS performed due to DCIS could be postponed after childbirth 1+
116
OncOlOgy in clinical practice 2017, Vol. 13, No. 3
D.11. Surgical management decreasing 
the risk of breast cancer morbidity
Dawid Murawa, Zbigniew I. Nowecki,  
Arkadiusz Jeziorski
 — Surgical management decreasing breast cancer mor-
bidity could pertain to the patients with diagnosed 
breast cancer as well as non-cancer patients, with 
confirmed genetic changes or positive family history 
regarding breast cancer.
 — Patients with breast cancer based on inherited muta-
tions account for a few per cent of the whole group 
breast cancer patients. The risk of cancer develop-
ment depends on penetrance of the mutated gene.
 — Mutations in suppressive genes BRCA1 and 
BRCA2 are a syndrome of the highest genetic pre-
disposition to breast cancer development, increasing 
the morbidity more than 10-fold (3–5% of breast 
cancer patients are the carriers of those muta-
tions). Other genes with high penetration include: 
TP53 (Li-Fraumeni syndrome) and PTEN (Cowden 
syndrome). Syndrome of moderate predisposition 
to breast cancer morbidity is connected with muta-
tions in the following genes: ATM, BRIP1, CHECK2, 
and PALB2 (2–3-fold higher risk compared to the 
general population).
 — The group at high risk (with morbidity risk more 
than 10-fold higher than in the general population) 
include patients:
• with confirmed BRCA1 or BRCA2 mutation,
• with family history indicating ≥ 3 cancers in first- 
or second-degree relatives,
• with first-degree relatives diagnosed with breast 
and ovarian cancer.
 — The group at high risk (with morbidity risk less 
than 10-fold higher than in general population) 
includes patients:
• without confirmed BRCA1 mutation,
• with family history: three cancers in first- or 
second-degree relatives under 50 years of age, 
or three cancers regardless of age.
 — Mastectomy in the age range 40–50 years in women 
at high and very high risk of breast and/or ovarian 
cancer development decreases this risk by 90–95%.
 — Bilateral adnexectomy (at the age 35–40 years 
— based on criterion of the youngest ovarian cancer 
patient in a family or end of reproductive period) in 
women at high and very high risk of breast and/or 
ovarian cancer development decreases this risk 
by 50%.
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Subject Surgical management 
decreasing the risk of 
breast cancer morbidity
Analysed problems PSSO recommendation
Women with confirmed genetic changes or with positive family history of breast cancer should be 
under the control of an outpatient clinic for genetic counselling within the program of taking care 
of families at high, inherently conditioned risk of breast and ovarian cancer development — a part 
of the Ministry of Health National Programme for Combating Cancer
2+
Besides patients with confirmed genetic changes and strong positive family history according 
breast cancer, the patients receiving during childhood irradiation of chest wall (e.g. with Hodgkin’s 
disease) should also be qualified to surgical management decreasing the risk of breast cancer 
development
2+
Surgical management in female patients at higher risk of breast cancer development, 
without diagnosis
Both, uni- and bilateral mastectomy is not indicated in women without clearly defined genetic 
cancer risk factors
1+
The procedure of qualification to surgical operation decreasing the risk of breast cancer should be 
initiated according to the patient’s request
2+
cont. Æ
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D.12. Breast cancer in elderly patients
Sylwia Grodecka-Gazdecka
 — Patients at the age > 65 years are genetically 
very heterogeneous.
 — Therapeutic approach should be based on biological 
patient’s age, being a result of calendar age, per-
formance state, concomitant diseases, nutritional 
state, general health, and life style. Patient’s prefer-
ences and potential toxicities should also be taken 
into consideration.
 — Comprehensive geriatric assessment (CGA) is the 
most complex tool to analyse independent predictive 
factors of morbidity and mortality of elderly patients 
and their “functional reserve”.
 — The most commonly used tools for functional re-
serve include:
• Charlson Comorbidity Index — a good indicator 
of survival over 10 years,
• 12-indicator test assessing four-year risk of death,
• IADL — Lawton scale, G8 test,
• Geriatric Prognostic Index.
 — PSSO recommends, for breast cancer patients, the 
use of a geriatric assessment chart for oncological 
patients over 65 years of age (Appendix 2), in which:
• patients receiving the number of points rang-
ing between 87 and 100 (“fit patients”) are not 
Analysed problems PSSO recommendation
Qualification to surgical treatment is performed after:
 —   consultancy of a clinical geneticist, based on the results of tests essential to assess the risk  
  of breast cancer
2+
 —   physical examination and imaging tests (mammography, USG, MRI) 2+
 —   consultancy and assessment by a psycho-oncologist, as well as sexologists and  
  gynaecologists if required
2+
 —   MDT decision 2+
Mastectomy conserving the nipple–areola complex with reconstruction at the same time  
(or without reconstruction) is a recommended surgical management
1+
There are no indications to routine verification of the lymphatic system using SLNB 2+
ALND of regional confluence as a diagnostic procedure is not recommended 2+
Surgical management in female patients at higher risk of breast cancer development, with 
breast cancer diagnosed in one breast
Qualification to breast cancer treatment is based on standard diagnostic procedure and MDT 
decision
2+
Mastectomy with verification of regional lymphatic confluence is a recommended surgical 
management, according to current standards
2+
BCT with verification of regional lymphatic confluence is an acceptable surgical management, 
according to current standards
1+
Adjuvant treatment is provided according to current standards of breast cancer patients, based on 
MDT decision*
2+
Surgical management decreasing the risk of cancer development in the opposite breast in 
female patients at higher risk of breast cancer, with breast cancer diagnosed in one breast
The procedure of qualification to surgical operation decreasing the risk of cancer in the opposite 
breast should be initiated according to the patient’s request (mastectomy with reconstruction at 
the same time is suggested)#
1+
Indications to mastectomy decreasing the risk of cancer should consider age at breast cancer 
diagnosis and information regarding evaluated genetic abnormalities
2+
Surgical management decreasing the risk of cancer development in the opposite breast in 
female patients diagnosed with episodic breast cancer
According to current clinical trials, surgical management decreasing the risk of cancer development 
in the opposite breast in female patients diagnosed with episodic breast cancer is not 
oncologically justified because it does not lead to decreased cancer risk in the opposite breast 
and does not impact breast cancer-dependent survival
2+
*Participation in clinical trials is recommended. #Patient’s prognosis should be analysed
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burdened with the risk of more intensified early 
complications than patients in other age groups,
• in patients receiving the number of points rang-
ing between 74 and 86 (“vulnerable patients”) 
complex geriatric assessment and treatment 
modification should be considered,
• patients receiving the number of points below 
74 (“frail patients”) are qualified to the group 
at very high complication risk and should be 
very carefully qualified to surgical operation and 
treated as “frail” patients.
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Subject Breast cancer in elderly 
patients
Analysed problems PSSO recommendation
Patient’s health status should be assessed according to the recommendations of PSSO’s GONG 
section
2+
Patients aged > 65 years in good general state (expected survival time > 5 years and acceptable concomitant diseases)
Treatment according to the standards 2+
Surgical treatment as in younger patients 2+
For regional confluence assessment, SLNB is recommended 2+
Neo- and adjuvant treatment should be based on MDT decision, suggested standpoint of the surgical oncologist
Endocrine therapy for hormone-dependent breast cancers 1+
Standard chemotherapy protocols < 70 years 1+
Standard chemotherapy protocols > 70 years 1+
Anti-HER2 therapy (trastuzumab) 1+
Radiotherapy 1+
Patients aged > 65 years with poor general state (“frail”) — expected survival time < 5 years and significant concomitant 
diseases
Therapeutic decision of MDT based on assessment of patient’s general state 2+
Reduction of standard treatment 1+
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Appendix 2. GONG 
GONG — Geriatric Oncology Group
GERIATRIC ASSESSMENT CHART FOR ONCOLOGICAL PATIENTS OVER 65 YEARS OF AGE
..............................................................................................
First name and surname
............................................
Age
............................................
PESEL
..............................................................................................
Address
..............................................................................................
Phone
Diagnosis: clinical ....................................................................................................................................................................
histological ...............................................................................................................................................................................
PATIENT’S OWN                        Excellent (3 points) 
HEALTH                                    Good (2 points) 
ASSESSMENT                            Bad (1 points)
PERFORMANCE STATE
“Stand up and go” test (3 points — 1 point)
“Stand up from chair, go 3 m, turn around, come back, and 
sit down”
7–10 sec. = 3 points; 10–20 sec. = 2 points;
> 20 sec. = 1 point
BODY  
MASS  
INDEX
Normal 18.5–25 (6 points)
< 18.5 underweight (2 points)
> 25 overweight (2 points)
CREATININE CONCENTRATION: normal (1 points), abnormal (0 points)
BASIC DAILY LIFE FUNCTIONS  
(modified Katz Index)
 
points
COMPLEX DAILY LIFE FUNCTIONS  
(modified Lawton scale)
 
points
1. Taking a shower 1. Shopping
2. Dressing up 2. Preparing meals
3. Eating 3. Washing
4. Using toilet 4. Home repairs
5. Urination and defecation control 5. Cleaning
6. Moving 6. Calling
7. Bending 7. Money management
8. Crouch 8. Using public transportation
9. Raising arms 9. The reach to 500 m
10. Wearing a weight of 5 kg 10. Taking drugs
Yes — 3 points; With help — 2 points; No — 1 point Yes — 3 points; With help — 2 points; No — 1 point
CONCOMITANT DISEASES (underline)
Cardiac disease, hypertension, pulmonary diseases, breathing disorders, gastrointestinal diseases, hepatic diseases,  
urinary tract diseases, renal chronic insufficiency, diabetes, atherosclerosis, Parkinson’s disease, Alzheimer’s disease
3 diseases (1 point)
2 diseases (2 points)
1 disease (3 points)
No diseases (6 points)
body mass in kg
growth in m²
BMI = ----------------------- =.............
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ELDERLY SYNDROMES (underline)
Dementia, depression, urinary incontinence, bowel incontinence, imbalance, sight, hearing, taste disturbance,  
chronic constipation, taking many medications
3 syndromes (1 point)
2 syndromes (2 points)
1 syndrome (3 points)
No syndromes (6 points)
MENTAL STATUS (2 points–1 point)
Orientation in time (year, month, day)   
Orientation in place (country, city, location)   
Please repeat and try to memorise the address I will give you: 42 Gruszkowa street   
SOCIOECONOMIC SITUATION
Good living conditions (3 points); bad (1 point)   
Health insurance (yes — 3 points); (no — 1 point)   
Home care (yes — 3 points); (no — 1 point)   
SUM OF POINTS (max 100) %   
INTERPRETATION OF RESULT’S — for management please see PSSO Consensus for breast cancer management
87–100 points — patient without complications risk — “fit patient”
74–87 points — patient at higher risk — “vulnerable patient”
< 74 points — patient at very high risk — “frail patient”
Date of evaluation................................ Signature of evaluated person......................................
D.13. Breast cancer in male patients
Dariusz Nejc
 — Breast cancer in male patients is very rare, as in 
postmenopausal women. The most common is NST 
cancer, ER-positive, PR-positive.
 — General factors of breast cancer development risk in 
male patients include mutations (especially BRCA2), 
Cowden syndrome, Klinefelter’s syndrome, hyperoes-
trogenism (endogenous and exogenous), and previous 
chest radiotherapy. Gynaecomastia is not a risk factor 
for breast cancer development in male patients.
 — Screening is not recommended in the general 
male population.
 — Endocrine therapy is a basic supplemental systemic 
treatment (with tamoxifen preferred, and aromatase 
inhibitors not recommended).
 — Prognosis in male and female breast cancer patients 
(at the same age and with the same clinical stage) 
is similar.
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Subject Breast cancer  
in male patients
Analysed problems PSSO recommendation
Diagnosis
Standard diagnosis (regardless of gender)
Diagnosis is based on histological evaluation
Before treatment initiation, mammography, USG of both breasts and axillary lymph nodes, chest 
X-ray, as well as abdominal and pelvic USG should be performed
2+
Treatment
Treatment is based on MDT decision 2+
The choice of surgical method is based on the same principles of breast cancer treatment, regardless 
of gender
2+
cont. Æ
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Analysed problems PSSO recommendation
SLNB — recommended during diagnosis of regional lymphatic basin 2+
Neo- and adjuvant treatment should be based on MDT decision, suggested standpoint of the 
surgical oncologist:
Radiotherapy — standard (regardless of gender) should be considered according to anatomical 
conditions in men
Chemotherapy — standard (regardless of gender)
Endocrine therapy (tamoxiphen preferred)
2+
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E.1. Inflammatory breast cancer
Arkadiusz Jeziorski
 — Inflammatory breast cancer is a rare malignancy, 
accounting for 1–5% of all breast cancers.
 — Inflammatory breast cancer develops in microfocal 
form, which gives massive metastases through lym-
phatic vessels, leading to their occlusion. According 
to metastases’ features, there are very early specific 
clinical signs and symptoms:
• redness and excessive warming of breast,
• breast enlargement resulting from lymphat-
ic oedema,
• breast painfulness,
• skin takes the form of peau d’orange.
 — Imaging diagnosis (mammography, USG, MRM) is 
inefficient in the majority of cases.
 — Diagnosis of inflammatory breast cancer is based on 
clinical picture and histological evaluation of skin 
sample, with embolism in vessels from cancer cells.
 — Therapy of inflammatory breast cancer is combined 
and based on MDT decision.
 — Surgical treatment (never as initial treatment of in-
flammatory breast cancer, most commonly as second 
stage, after neoadjuvant chemotherapy) is based on 
Madden mastectomy.
 — Sentinel lymph node biopsy is contraindicated in 
this cancer type.
 — Clinical classification of inflammatory breast cancer 
is T4cN0-3.
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E. DETAILED INDICATIONS
Subject Inflammatory breast 
cancer
Analysed problems PSSO recommendation
Histological diagnosis after skin biopsy 1+
Clinical classification at diagnosis of inflammatory breast cancer is cT4d 2+
Therapeutic approach
Multidisciplinary treatment:
preoperative chemotherapy, surgery, radiotherapy
2+
Surgical treatment:
Madden mastectomy after preoperative chemotherapy 2+
BCT 1–
SLNB 2–
Postoperative treatment is based on MDT decision 2+
E.2. Paget’s disease of nipple with 
concomitant breast cancer
Janusz Piekarski, Arkadiusz Jeziorski
 — Clinical symptoms of Paget’s disease of nipple 
include ulcerations, erosions, scabs, redness, or 
eczema, on the top of the nipple, and very often 
itching, painfulness or leakage from the nipple; 
these symptoms can be accompanied by palpable 
breast tumour.
 — Paget’s disease of nipple could has an isolated form 
(Paget’s disease of nipple alone) or together with 
concomitant breast cancer (DCIS or invasive can-
cer).
 — Breast cancer accompanying Paget’s disease of 
nipple could be located directly behind the nipple 
and/or peripherally. A high percentage of infiltrat-
ing cancers and/or DCIS concomitant with Paget’s 
disease of nipple are multifocal and/or multicentre.
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E.3. Occult breast cancer
Arkadiusz Jeziorski, Janusz Piekarski
 — Occult breast cancer (carcinoma occultum mammae) 
is diagnosed in patients with metastases to axillary 
lymph nodes, but physical examination as well as im-
aging tests: mammography (MMR), ultrasonography 
(USG) and magnetic resonance imagination (MRI) 
do not reveal a tumour in breast tissue.
 — Diagnosis is directed towards excluding of metastasis 
of adenocarcinoma from other organs.
 — In the case of lack of abnormalities in imaging test 
(MMR, USG, and MRI) in a breast, radiotherapy 
is an alternative for mastectomy together with lym-
phadenectomy.
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Subject Paget’s disease of nipple 
with concomitant  
breast cancer
Analysed problems PSSO recommendation
Diagnosis
Diagnosis of Paget’s disease of nipple is confirmed by histological evaluation of excision sample 
taken from pathological changes on the nipple. The sample should include the full thickness of the 
nipple skin
2+
When histological evaluation does not confirm Paget’s disease, and changes on the top of the 
nipple do not recover after conservative treatment, taking a sample form a nipple top should be 
taken once more
2+
Imaging diagnosis including mammography and USG of the breast 2+
When mammography and USG do not indicate pathological changes in the breast, MRI should be 
considered
1+
Diagnosis of concomitant breast cancer is based on histological evaluation of the tumour sample 2+
Treatment
Surgical management depends on the type of Paget’s disease
In patients with isolated Paget’s disease of nipple without concomitant breast cancer, surgical 
operation includes removal of the nipple–areola complex (R0 resection)
2+
In patients with isolated Paget’s disease of nipple there are no indications to SLN biopsy or axillary 
lymphadenectomy. Additionally, there are no indications to supplemental radiotherapy
2+
If Paget’s disease is accompanied by breast cancer (DCIS and/or invasive cancer), adjuvant treatment 
is based on principles regarding the treatment of breast cancer patients
2+
If Paget’s disease is accompanied by breast cancer:
 — there is possible surgical conserving treatment with supplemental radiotherapy. Operation 
include removal of the nipple-areola complex with margins of healthy tissues located behind 
the nipple (R0 resection) together with concomitant breast cancer (there is no requirement to 
dissect the tissues en block)
 — management with axillary lymph nodes is according to the principles of breast cancer patients
2+
Mastectomy is a treatment of choice in patients with change in nipple accompanied by multiple 
focuses of breast cancer in different parts of the gland
2+
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E.4. Bilateral breast cancer
Janusz Piekarski, Arkadiusz Jeziorski
 — Bilateral breast cancer is diagnosed in patients with 
two primary cancers of both breasts. The term bilateral 
breast cancer does not include patients with unilateral 
breast cancer and its metastasis in the opposite breast.
 — Primary cancer of the opposite breast has the fol-
lowing features:
• histological type is different from histology of 
first cancer,
• infiltrating cancer is accompanied by non-infil-
trating component (in situ),
• in the case of the same histological cancer type 
in both beasts, there are no metastases in axil-
lary lymph nodes (or they are few) and distant 
metastases (satellite metastases).
 — Bilateral breast cancer is:
• simultaneous — cancer diagnosed at the same 
time in both breasts,
• synchronic — when the time period between 
diagnosis of both cancers is no longer than 
six months,
• metachronic (asynchronic) — when the time 
period between diagnosis of both cancers exceeds 
six months.
Subject Occult breast cancer
Analysed problems PSSO recommendation
Diagnosis
Mammography, USG 2+
MRI 2+
PET 1+
Clinical staging 2+
CB of lymph nodes (HP test) 2+
HP test: detection of metastasis of adenocarcinoma. IHC assessment: ER, PR, HER2, and other tests 
excluding metastases from other organs
2+
Treatment
Based on MDT decisions 2+
Axillary lymphadenectomy (level I/II/III) 2+
Systemic treatment depending on state of lymph nodes 2+
Axillary lymph nodes cN1:
Treatment — lymphadenectomy
2+
Axillary lymph nodes cN2:
Treatment — systemic neoadjuvant treatment and then lymphadenectomy
2+
In the case of lack of cancer changes in breast MRI, mastectomy and breast irradiation are 
equivalent therapeutic methods
1+
Lymph node irradiation 1+
Subject Bilateral breast cancer
Analysed problems PSSO recommendation
Diagnosis
Imaging and histological diagnosis is performed according to the diagnostic and therapeutic 
principles for patients with unilateral breast cancer
2+
Treatment
Treatment of patients with bilateral breast cancer is based on the general principles of breast cancer 
treatment and MDT decisions
2+
Therapeutic decisions are made separately for each breast cancer, taking into consideration the 
clinical stage in each breast, and the possibility of summation of adverse events (e.g. radiotherapy 
administered for left and right chest side) as well as cosmetic issues (symmetry)
2+
Recommended surgical treatment is bilateral mastectomy with possible reconstruction 1+
Conserving treatment of both breasts in patients with bilateral breast cancer should be treated as 
a therapeutic option, possible to perform in reference centres
2+
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E.5. Tumour phyllodes of breast
Jerzy W. Mituś, Wojciech M. Wysocki
 — Treatment of non-malignant tumour phyllodes, 
characterised by good prognosis (recurrences in 8% 
of patients) is based on wide dissection of tumour 
with a 1-cm margin.
 — The ability of non-malignant and borderline tumour 
phyllodes (after initial excision) to recur and trans-
form into malignant type has been documented.
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Subject Tumour phyllodes of 
breast (borderline and 
malignant type)
Analysed problems PSSO recommendation
Treatment of primary tumour
Treatment of tumour phyllodes is based on wide excision with ≥ 1 cm margin or simple mastectomy 
(when wide excision does not allow proper wide operation margin)
2+
Incomplete excision (R1 resection) requires repeat operation (repeat wide excision or 
simple mastectomy)
2+
There are no indications to SLNB or ALND if clinically changed lymph nodes are absent 2+
Systemic treatment and radiotherapy used in adjuvant therapy require MDT agreement
Supplemental systemic treatment:
MDT decision; suggested standpoint of surgical oncology
Postoperative systemic treatment (chemotherapy) does not influence overall survival time and risk of 
local recurrence
1+
Endocrine therapy is completely inefficient 1+
Treatment of local recurrence
Local recurrence should be completely dissected (R0 resection) 2+
In case of incomplete dissection of local recurrence (R1 resection), radiotherapy and chemotherapy 
should be considered
0
After dissection of local recurrence radiotherapy should be considered 1+
Treatment of systemic dissemination:
MDT decision; suggested standpoint of surgical oncology
Surgical management of distant metastases is in accordance with recommendations for distant 
metastases of soft tissue sarcomas
2+
Radiotherapy: MDT decision; suggested standpoint of surgical oncology
Postoperative radiotherapy after R0 resection with ≥ 1 cm margin is not recommended 1+
After resection R0 with < 1 cm margin supplemental radiotherapy should be considered 0
E.6. Metaplastic breast cancer
Janusz Piekarski, Arkadiusz Jeziorski
 — Metaplastic breast cancer is diagnosed based 
on the presence of different tissues in NST his-
tological structure. There are two groups of 
metaplastic breast cancers: epithelial-epithelial 
(e.g. adenosquamous carcinoma) and epithelial- 
-mesenchymal.
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E.7. Breast lymphoma
Jacek Zieliński
 — Breast lymphoma could be a primary disease or 
a symptom of generalised neoplastic process. Pri-
mary breast lymphomas are very rare and account 
for 0.04–0.5% of breast malignancies.
 — The majority of primary breast lymphomas are B-cell 
non-Hodgkin’s lymphomas.
 — Diagnosis of breast lymphoma is based on the fol-
lowing criteria:
• histological evaluation (open biopsy is recom-
mended),
• presence of lymphoma in breast gland tissue 
and/or in regional lymph nodes, if they appeared 
at the same time,
• lack of lymphoma localised outside the breast.
 — Treatment of breast lymphoma is analogous to the 
treatment of lymphomas in different localisations, 
and it is based on histological diagnosis and clini-
cal stage.
 — The main method of breast lymphoma treatment 
is chemotherapy and/or radiotherapy. Mastectomy 
is not recommended due to the lack of impact of 
this method on survival time and prevalence of lo-
cal recurrences.
 — After breast reconstruction operations with use of 
implants, there is a possibility of T-cell lymphomas 
ALCL-ALK (–) (anaplastic large cell lymphoma). Of 
note, it is very rare — approximately 200 case were 
reported worldwide to date. The main clinical symp-
tom of this type of lymphoma is the appearance of 
exudate inside the capsule surrounding the implant. 
Diagnosis is based on cytological assessment of the 
effusion sample and tissue biopsy in order to get an 
appropriate histological evaluation.
 — When lymphoma is diagnosed after reconstruction 
breast operation capsulotomy is indicated.
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Subject Management of 
metaplastic breast cancer
Analysed problems PSSO recommendation
There are no specific clinical and radiological symptoms of metaplastic breast cancers. Based on 
those symptoms metaplastic breast cancer could not be clearly clinically diagnosed
2+
Diagnosis is established on histological evaluation 2+
If the core-needle biopsy sample is not representative, then decisive meaning is given to the 
excisional biopsy and histological evaluation of the tumour
2+
Essential during diagnosis of metaplastic cancers is differentiation with sarcomas as regards 
distinctness in clinical course and treatment of both cancers
2+
The choice of surgical treatment is based on the same principles as in NST in the same clinical 
stage
2+
Qualification to supplemental treatment has to be agreed during an MDT meeting 2+
Follow-up after treatment cessation is conducted according to the principles typical for other 
breast malignancies
2+
Subject Breast’s lymphoma
Analysed problems PSSO recommendation
Diagnosis
Diagnosis of breast lymphoma is based on the following criteria:
 — histological evaluation (open biopsy recommended)
 — presence of lymphoma in breast tissue and/or in regional lymph nodes, if they appeared at the 
same time
 — lack of lymphoma localised outside the breast
2+
cont. Æ
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E.8. Cancer metastases to the breast
Janusz Piekarski, Arkadiusz Jeziorski
 — Cancer metastases to the breast, especially single and 
being a first symptom of malignancy, are very rare. 
In approximately 1/3 of cases the primary location 
of cancer at diagnosis of metastases to the breast 
is unknown.
 — The most important risk factor for cancer metas-
tases to the breast is previously diagnosed other 
malignant disease.
 — The malignancy, which is the most common source of 
distant metastases in the breast is cancer of the op-
posite breast. The frequency of metastases of breast 
cancer to the opposite breast is definitely lower than 
the prevalence of bilateral breast cancer (e.g. two 
primary cancers in both breasts). The second most 
common are secondary sites of lymphatic malig-
nancies and melanoma, followed by: lung cancer, 
ovarian cancer, prostate cancer, renal cell cancer, 
and gastric cancer.
 — The most common clinical form of cancer metastases 
to the breast is tumour: painless, solid, circular or 
oval, and movable against surrounding tissues. Clini-
cally it is similar to a fibroadenoma.
 — Cancer metastases to the breast could be single or 
multiple changes. In more than 50% of patients there 
are also concomitant metastases to axillary lymph 
nodes detected.
Analysed problems PSSO recommendation
A recommended form of diagnosis is taking a histological sample during open biopsy 2+
Each patient, after receiving a histological result, has to be presented to the MDT in order for 
qualification to appropriate treatment
2+
Treatment
Treatment of breast’s lymphoma is analogous to the treatment of lymphomas in different 
localisations, and it is based on histological diagnosis and clinical stage
2+
The main method of breast lymphoma treatment is chemotherapy and/or radiotherapy 2+
Mastectomy is not recommended due to lack of impact of this method on survival time and 
prevalence of local recurrences
0
After breast reconstruction operations with use of implants, there is a possibility of T-cell lymphomas 
(anaplastic large cell lymphoma, ALCL). The main clinical symptom of this type of lymphoma is the 
appearance of exudate inside the capsule surrounding the implant. Diagnosis is based on cytological 
assessment of an effusion sample and tissue biopsy in order to obtain an appropriate histological 
evaluation
2+
When ALCL is diagnosed after reconstruction breast operation, capsulotomy is indicated as well as 
possible further treatment based on the MDT decision (radiotherapy +/– chemotherapy)
2+
Subject Cancer metastases  
to breast
Analysed problems PSSO recommendation
Diagnosis 2+
During clinical diagnosis detailed medical history is mandatory, especially toward previous other 
malignant diseases
2+
Diagnosis is based on histological evaluation 2+
Each patient, after receiving a histological result, has to be presented to the MDT in order to qualify 
to appropriate treatment
2+
Treatment 2+
Treatment is relevant to primary cancer diagnosed and led by the MDT 2+
Surgical treatment of cancer metastases to the breast is limited to local tumour dissection for either 
diagnostic or cytoreductive purposes
2+
Mastectomy is indicated in the case of bleeding from the tumour 2+
Follow-up schedule after treatment cessation depends on the primary tumour diagnosed 2+
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E.9. Primary stage IV breast cancer
Arkadiusz Jeziorski
 — Advanced breast cancer means that at diagnosis 
of the disease there are already distant metasta-
ses present.
 — Advanced breast cancer is incurable in almost all 
cases, and treatment is aimed to prolongation of 
survival time and symptoms relief.
 — The choice of appropriate treatment strategy is 
based on the MDT decision and depends on the 
patient’s general state, local cancer advancement, 
prognostic and predictive factors, as well as the 
presence and type of clinical symptoms.
 — The main therapy method is systemic treatment.
 — According to indications, surgical treatment is a pal-
liative care.
Subject Primary stage IV  
breast cancer
Analysed problems PSSO recommendation
The main therapy method is systemic treatment, according to the MDT decision 2+
Surgical treatment is a palliative care, relieving the symptoms or protecting against 
haemorrhage
2+
Surgical treatment of the primary tumour could be considered in the case of stable bone 
metastases (if it is the only localisation of disease spread) after a few months of systemic 
treatment, upon patient’s request, and after MDT decision
0
E.10. Angiosarcoma and other 
sarcomas of the breast
Piotr Rutkowski, Zbigniew I. Nowecki
 — Due to the very low prevalence of breast sarcomas 
there is no treatment schedule specifically developed 
for this type of malignancy. Recommendations re-
garding treatment of sarcomas in other localisations 
should be implemented.
 — Primary angiosarcoma (AS) accounts for only 0.05% 
of all breast malignancies. It is estimated that one case 
of primary AS is noted per 1700–2000 primary breast 
cancers. This comes to approximately seven cases 
per million women. Secondary AS is connected with 
chronic extremity oedema after mastectomy (Stew-
art-Treves syndrome) and previous radiotherapy.
 — Taking into account the high aggressiveness of AS, 
the management of choice, giving the best results, 
is combined treatment with surgery and supplemen-
tary radiotherapy (even in patients with secondary 
angiosarcoma) +/– perioperative chemotherapy.
 — By analogy to soft tissue sarcoma in different 
localisations, breast lymphoma is also very rarely 
connected with metastases in lymph nodes. Surgical 
treatment of choice should be simple mastectomy or 
radical local conserving dissection without axillary 
lymphadenectomy. Neo- and adjuvant radiotherapy 
(or possible chemotherapy) is recommended accord-
ing to treatment principles, similarly to sarcomas in 
different localisations.
References
1. Depla AL, Scharloo-Karels CH, de Jong MAA et al. Treatment and 
prognostic factors of radiation-associated angiosarcoma (RAAS) 
after primary breast cancer: A systematic review. European Journal 
of Cancer 2014; 50: 1779–1788.
2. Rutkowski P (ed). Mięsaki tkanek miękkich. Via Medica, Gdańsk 2015.
3. Soft tissue sarcoma. NCCN Clinical Practice Guidelines in Oncology, 
Version 1.2016.
4. The ESMO/European Sarcoma Network Working Group. Soft tissue 
and visceral sarcomas: ESMO Clinical Practice Guidelines for diagno-
sis, treatment and follow-up. Ann Oncol 2014; 25 (suppl 3): iiii102–112.
5. Voutsadaki IA, Zaman K, Leyvraz S. Breast sarcomas: Current and 
future perspectives. The Breast 2011; 20: 199e–204e.
Subject Combined treatment of 
angiosarcoma and other 
sarcomas of the breast
Analysed problems PSSO recommendations
Diagnosis
Standard imaging diagnosis: mammography, USG 2+
MRI of chest wall 2+
cont. Æ
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Analysed problems PSSO recommendations
Exact clinical staging (CT of chest and abdomen, brain MRI) 2+
Fine-needle aspiration 2–
Core-needle biopsy 2+
Treatment of primary lesions
Radical surgical treatment (R0) with/without muscle pectoral major 2+
BCT, if possible 0
ALND 1–
Neo-/adjuvant chemotherapy (after agreement in MDT) 0
Adjuvant radiotherapy, even in induced angiosarcoma, is a standard of postoperative treatment 1+
Adjuvant radiotherapy (in sarcomas other than AS) 1+
In case of impossible operation and/or radical operation, neoadjuvant chemotherapy (NEC) is 
indicated as initial treatment
1+
Treatment of local recurrence
R0 resection 2+
Radiotherapy, chemotherapy, especially after R1 resection 1+
NAC as initial treatment should be considered 1+
Treatment of metastases, inoperable local recurrence
Therapy based on MDT decisions, as for other sarcomas 2+
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F.1. Treatment of local recurrence after 
breast cancer therapy
Rafał Matkowski, Anna Kulik,  
Sławomir Mazur
 — Local ipsilateral breast tumour recurrence (IBTR) 
is a recurrence within the breast, chest wall, axillae, 
as well as supraclavicular, subclavicular, and retros-
ternal lymph nodes, after previous treatment per-
formed with radical intention (definition of Union 
Internationale Contre le Cancer [UICC]).
 — IBTR is diagnosed in approximately 2–20% of breast 
cancer patients, despite previous optimal treatment 
— this results from potential biological aggressive-
ness of the tumour. In this group of patients the risk 
of general spreading of the disease is 3–5-fold higher 
than in patients without local recurrence.
 — IBTR definition includes two different biological 
processes connected to the cancer: true recurrences 
(TR) and new primary tumours (NP). Primary lesion, 
from which TR comes, is characterised by a higher 
percentage of metastases to lymph nodes (37.8%), 
and short disease-free interval (DFI) — on average 
46.6 months. NP features include low percentage of 
metastases to lymph nodes (8.7%) and longer DFI 
(on average 62.1 months). Risk factors for TR are 
as follow: young age, positive margins, metastases to 
lymph nodes, and treatment without radiotherapy. 
Risk factors for NP include: young age, treatment 
without radiotherapy, and cancer in opposite breast 
after initial surgical treatment. Furthermore, NP 
shows significantly better prognosis — five-year 
overall survival (OS) is 71.0% in TR and 94.7% in 
NP; P = 0.022, so less intense treatment schemes 
could be considered (e.g. re-BCT).
 — Each patient, after receiving a pathology report 
confirming local recurrence, should undergo repeat 
staging (rTNM), analysis of expression of different 
receptors on cancer cells (ER, PR, HER2, and 
Ki67), and MDT discussion in order to qualify to 
individualised combined treatment.
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F. LOCO-REGIONAL RECURRENCES OF BREAST CANCER
Subject Treatment of local 
recurrence after breast 
cancer therapy
Analysed problems PSSO recommendation
Treatment of local recurrence after conserving breast cancer therapy
“Salvage mastectomy”
Mastectomy with the intention to achieve R0 2+
Skin-sparing mastectomy (SSM) with the intention to achieve R0 1+
Nipple-skin-sparing-mastectomy (NSM) with the intention to achieve R0 0
MDT decision, suggested standpoint of the surgical oncologist:
The decision to repeat XRT in patients after primary BCT and then after “salvage mastectomy” should be individualised:
Radiotherapy including chest wall +/– regional lymph nodes 0
Dose escalation in previously not irradiated fields (+10%)  1–
“Salvage” re-BCT
Repeat breast conserving treatment (re-BCT) with the intention to achieve R0 0
In patients after previous BCS, without radiotherapy, re-BCS requires supplemental radiotherapy 
— WBRT
2+
cont. Æ
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Analysed problems PSSO recommendation
MDT decision, suggested standpoint of the surgical oncologist:
In patients after previous BCS with radiotherapy, re-BCS requires repeat supplemental radiotherapy 1+
Surgical management in an axillary in patients with rcN0
SLNB after previous SLNB in the case of rcN0; if nSLN could not be identified, axillary 
lymphadenectomy is recommended
1+
SLNB after previous ALND in the case of rcN0 2–
Treatment of local recurrence after mastectomy
“Salvage surgery”
Radical treatment — R0 resection 2+
Palliative treatment — full-thickness chest wall resection 0
MDT decision, suggested standpoint of the surgical oncologist:
Radiotherapy
In patients without radiotherapy after previous mastectomy, supplemental radiotherapy should be 
used, including chest wall +/– regional lymph nodes (after recurrence dissection)
1+
Repeat irradiation (chest wall + hyperthermia) 0
Recurrence in axillary lymph nodes
RT of axillae after R0 resection in patients without previous RT of this area 1+
Repeat radiotherapy of axillae after R0 resection in patients after previous RT of this area 0
Recurrence in supraclavicular lymph nodes
Surgical treatment 0
Radiotherapy 1+
Recurrence in internal mammary lymph nodes
Surgical treatment 0
Radiotherapy 1+
MDT decision, suggested standpoint of the surgical oncologist:
In the treatment of local recurrence after consideration of biological subtype of cancer (ER, PR, 
HER2, and Ki67):
In patients after R0 resection:
Systemic treatment should be used, according to biological subtype 2+
In patients in whom R0 resection is not possible:
Palliative systemic treatment should be used, according to biological subtype 2+
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G.1. Reconstruction management 
in breast cancer patients — general 
indications
Piotr Pluta, Sławomir Cieśla
 — In each case of breast-conserving therapy (BCT) 
oncoplastic breast surgery (OBS) should be used in 
order to achieve radical oncology operation as well as 
good aesthetic effect after surgery and radiotherapy 
(aesthetic and functional results of 20–40% BCT 
operations without OBS are poor).
 — There are possible extensive resections of glandular 
breast tissue together with the tumour, including up 
to 50% of breast volume, with good aesthetic effect 
and adequately wide margins. The methods of onco-
plastic level II (relocation of tissue within breast) or 
III (replacement of loss with the tissue moved from 
out of the breast) should be used.
 — Comparing of traditional BCT and OBS techniques 
is in favour of OBS, including local recurrences, early 
complications, and aesthetic and functional results.
 — In women after mastectomy, reconstruction at the 
same time should be recommended only if absolute 
contraindications are excluded.
 — Radical dissection of glandular tissue with cancer 
together with skin-conserving or even nipple-areola 
complex should be supplemented with the recon-
struction performed at the same time with use of 
implants or patient’s own tissue, depending on 
surgery experience. It allows potential surgical cor-
rection later on.
 — Reconstruction of dissected breast influences not 
only the patient’s mental status, but also prevents 
abnormalities of normal body posture.
 — In each case of breast reconstruction, symmetrisa-
tion of healthy breast should be considered, either 
performed at the same time or delayed (enlargement 
or reduction with suspension).
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G. RECONSTRUCTION AND PLASTIC SURGERY IN ONCOLOGY
Subject Reconstructions  
in breast cancer  
— general indications
Analysed problems PSSO recommendation
Each female patient qualified to mastectomy should be informed about possible breast 
reconstruction
2+
The main situation in which indications to breast reconstruction are considered is the patient’s 
high motivation to undergo this surgical operation or sequential procedures
2+
Qualification to reconstruction procedure is based on careful analysis of the patient’s oncological 
as well as mental status
2+
Qualification to immediate reconstruction procedure is performed after comprehensive analysis 
and the decision of the MDT
2+
The choice of technique of breast reconstruction (operations with use of expanders/implants, 
autologous reconstructions) is based on site experience and the patient’s preferences
2+
Immediate procedures are preferable, due to their beneficial impact on patients’ life comfort and 
costs (despite higher risk of reconstruction failure)
1+
There are no oncological contraindications to delayed reconstruction 0
cont. Æ
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G.2. Reconstruction management  
in breast cancer patients — detailed 
indications
Artur Bocian, Krzysztof Kurczych,  
Daniel Maliszewski
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Analysed problems PSSO recommendation
An absolute contraindication to immediate reconstruction is inflammatory breast cancer 2+
Scheduled radiotherapy is not a contraindication to immediate reconstruction 0
The following factors should be considered as increasing complication risk and potentially 
influencing qualification to breast reconstruction:
 — BMI > 30
 — current smoking
 — diabetes
 — previous radiotherapy of chest wall
 — age — assessment of patient’s state according to PSSO GONG section recommendations
2+
Subject Reconstructions  
in breast cancer  
— detailed indications
Analysed problems PSSO recommendation
Operation type
A. Oncoplastic conserving operations
Reduction mammoplasty adapted to the tumour 2+
Techniques of local flaps 2+
Partial mastectomy with tissue transfer 2+
B. Mastectomy conserving skin/nipple (SSM/NSM)
Mastectomy conserving skin (SSM/NSM) is:
safe (frequency of recurrence is the same as after radical mastectomy) 2+
nipple–areola complex could be preserved 2+
could be performed after breast plastic surgery with mastopexia/reduction 2+
C. Types of bilateral mastectomy reducing risk of breast cancer (RRBM)
Simple mastectomy 1+
RRBM by SSM (skin sparing during mastectomy) 1+
RRBM by NSM (nipple-areola complex sparing) 1+
Prophylactic contralateral mastectomy 1+
Different reconstruction aspects
A. Reconstruction after mastectomy
Use of implants filled with silicone 1+
Reconstruction with autologous tissue 1+
Reconstruction with pediculated tissue 1+
Reconstruction with free transplant tissue 1+
Autologous tissue combined with implants 1+
B. Timing of reconstruction after mastectomy
Breast reconstruction at the same time — obligatory during SSM and NSM
Advantages — avoiding a syndrome after mastectomy and disturbances of supplemental 
treatment (CTH, RT)
1+
cont. Æ
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Analysed problems PSSO recommendation
Delayed breast reconstruction 
Disadvantages — lack of skin envelope
1+
“Delayed-immediate” breast reconstruction 0
C. Breast reconstruction depending on timing of radiotherapy
C.1. Implant reconstruction (IR)
Implant reconstruction (IR) in case of expected adjuvant radiotherapy 0
Primary reconstruction with expander and then with definitive prosthesis in case of expected 
adjuvant radiotherapy
0
IR without radiotherapy (XRT) 2+
IR after mastectomy before XRT 1+
IR after mastectomy and after XRT
Disadvantages — tissue fibrosis, problems with wound healing
0
IR after mastectomy due to recurrence after BCT 0
C.2. Breast reconstruction (BR) with autologous tissue TRAM or LD
BR after XRT 2+
BR before XRT
Disadvantages — tissue fibrosis, problems with wound healing, fat tissue necrosis
1–
D. Methods of restorations of breast and tissues after radical operations
D.1. Materials replacing tissue losses used during reconstructions (recommended 
participation in clinical trials)
Autologous tissue (e.g. autodermal transplant, flap from latissimus dorsi muscle — LD) 1+
Acellular dermal matrix (ADM) 1+
Synthetic mesh to muscle repair 1+
D.2. Lipotransfer
Lipotransfer after mastectomy and breast reconstruction 1+
Lipotransfer after BCT 1+
Transplants enriched with autologous adipose-derived stem cells (ASC) (in clinical trials) 0
D.3. Pediculated flaps
Breast reconstruction with autologous tissue TRAM, LD (both could be performed as techniques 
with muscle sparing)
1+
Delayed TRAM in patients with risk factors 1+
Pediculated TRAM from the same side 1+
D.4. Free tissue transfers
DIEP flaps 1+
Free flap TRAM 1+
SIEA flap 1+
SGAP/IGAP flap 1+
Free lobular transplant with gracilis muscle (TMG) 1+
Free tissue transfers:
Patients’ satisfaction after use of free tissue transfers was not higher than for pediculated flaps.
Advantages:
 — flaps: DIEP and free TRAM are the procedures that are potentially muscle sparing.
With the use of DIEP flaps, there was a lower proportion of abdominal hernias.
Disadvantages:
 — time-consuming and absorbing staff procedure
 — intensified preoperative monitoring
 — higher percentage of re-operations and general failure
 — RT before reconstruction increases the frequency of vascular complications
cont. Æ
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Analysed problems PSSO recommendation
D.5. Combined reconstruction technique: flap–implant
Flap from latissimus dorsi muscle — LD(LD) + implant
 — reconstruction after RT
 — reconstruction before RT
1+
1+
Other flaps + implant 0
Note:
Advantages: like for tissues after XRT; appropriate implant coverage; TRAM: preferred stepwise 
procedure
Disadvantages: muscle constructions (LD flap)
E. Other reconstruction aspects that should be considered in specific situations
Symmetrisation of opposite breast 2+
Re-operation to improve aesthetic effect in reconstructed breast 2+
Reconstruction of nipple-areola complex 2+
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H.1. Follow-up after breast cancer 
treatment
Arkadiusz Jeziorski, Zbigniew I. Nowecki
During follow-up after radical treatment, the follow-
ing are recommended:
 — systematic monthly self-control,
 — promoting healthy lifestyle, physical activity, and diet 
counselling in obese women,
 — unlimited access to rehabilitation and services, al-
lowing minimisation of physical, mental, and social 
consequences of breast cancer treatment.
H. FOLLOW-UP AFTER TREATMENT CESSATION
Recommended tests Frequency PSSO recommendation
Self-control Once per month 2+
Physical examination First 2 years — every 3–6 months
During 3–5 years — every 6 months
After 5 years — every 12 months
2+
Mammography and breast USG Every 12 months
 After BCT — first imaging 6 months after 
operation
2+
Gynaecological examination Every 12 months — special attention in 
patients treated with tamoxifen
2+
Densitometry in women during HTH Every 24 months — special attention in 
patients treated with aromatase inhibitors
1+
Body weight assessment BMI within the range 20–25 1+
Additional laboratory and imaging tests According to individual clinical indications 2+
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